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INTRODUCTION 

INTRODUCTION 
The haemostatic mechanism is a dynamic balance which can basically be described as 
the equilibrium between fibrin formation (coagulation) and fibrin lysis (fibrinolysis). 
A schematic presentation of the haemostatic balance is given in Figure I. 
Activation of the coagulation cascade is a physiologic response to tissue injury, and 
results in the formation of fibrin. Fibrin formation and deposition are a fundamental 
process in the repair of injured tissue and protect the body against haemorrhage. Fibrin 
is formed from fibrinogen, a reaction catalyzed by thrombin (!Ia) which is generated 
after contact activation or tissue activation of a cascade of proteolytic enzymes. The 
process of coagulation is controlled by coagulation inhibitors of which antithrombin !II 
(AT-lll) and protein Care the most important. 
Normal fibrin formation ar.d deposition are temporary reactions, which are curtailed or 
reversed when the initiating stimulus is removed, in order to restore normal tissue 
structure and function . Fibrin deposition is counterbalanced by the fibrinolytic system 
that lyses both fibrin and fibrinogen. Plasmin is the enzyme responsible for lysis of 
fibrinogen and fibrin. Plasmin is formed through activation of plasminogen by 
activators, such as tissue-type plasminogen activator (t-PA) and urokinase-type 
plasminogen activator (u-PA). Fibrinolysis is controlled by inhibitors of the 
plasminogen activators (PAl) and inhibitors of plasmin. such as a,-antiplasmin, a,-
macroglobulin and C1-inactivator. 
Disruption of the haemostatic balance may occur when activation of coagulation is 
insufficiently counteracted by coagulation inhibitors or when reactive fibrinolysis is 
inhibited. Under those circumstances, patients are exposed to the risk of 
thromboembolism or multiple organ failure due to widespread intravascular deposition 
of fibrin. Consumption coagulopathy. due to increased turnover of plasma coagulation 
factors may, after a phase of hypercoagulability. change into hypocoagulopathy and 
haemorrhagic diathesis. Consumption coagulopathy may exist alone, it may be 
accompanied by slight secondary fibrinolysis or the secondary hyperfibrinolysis may 
predominate. The hyperfibrinolysis is a consequence of an excessive production of 
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plasmin with degradation of fibrin, fibrinogen and of coagulation factors and the 
appearance of fibrin and fibrinogen degradation products, which in turn inhibit fibrin 
polymerization and promote a haemorrhagic diathesis. Finally, lysis of fibrinogen 
(primary fibrinolysis of fibrinogenolysis) may occur alone, leading to a haemorrhagic 
state through formation of fibrinogen degradation products which have anticoagulant 
properties. 
Analysis of the haemostatic balance in patients at risk for thromboembolism or bleeding 
is essential when treatment is considered. Disturbances of the haemostatic balance will 
be reflected by the concentration and composition of the products of the two opposing 
processes of coagulation and fibrinolysis - fibrin and fibrinogen derivatives - which can 
be used as markers of the status of the haemostatic balance. 
With improved understanding of the basic mechanisms of thrombosis and haemostasis, 
there has been a rapid development of techniques to assess the haemostatic system and 
its associated disorders. One of the newer systems that has recently become available 
for the assessment of haemostatic disorders. both thrombotic and haemorrhagic, is the 
determination of fibrin degradation products (FbDP) and fibrinogen degradation 
products (FgDP) in plasma by enzyme immuno assays (EIA's) based on monoclonal 
antibodies. 
This thesis comprises studies with monoclonal antibody-based plasma assays for 
derivatives of fibrin and fibrinogen in patients with diseases and conditions 
characterized by an activated state of coagulation and fibrinolysis. 
The aims of the study were: 
I. To review the clinical relevance of existing serum-based assays for 
fibrin/fibrinogen degradation products in comparison with the newly developed 
plasma-based assays for fibrin degradation products (FbDP, D-dimer). for the 
total of fibrin and fibrinogen degradation products (TOP) and for fibrinogen 
degradation products (FgDP), on the basis of published studies. 
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2. To evaluate the assays for D-dimer, FbDP, FgDP and TDP in healthy volunteers 
and patients with an activated state of coagulation. 
3. To study the haemostatic balance in diseases or conditions associated with an 
activated state of coagulation: 
a) patients with a suspected or proven thrombotic process. 
b) patients with cirrhosis of the liver to see whether haemostatic imbalance 
is due to primary fibrinolysis or diffuse intravascular coagulation. 
c) patients with septic shock to see whether haemostatic complications are 
due to increased activation of coagulation or inhibition of fibrinolysis. 
d) patients with an increased tendency to develop thrombotic complications 
who are treated with heparin, using measurements of fibrin degradation 
products, in order to evaluate effectiveness of treatment. 
4. To evaluate the diagnostic value of the D-dimer assay for deep venous 
thrombosis using receiver operating characteristic methodology and Baysian 
analysis. 
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Chapter 1 
MONOCLONAL ANTIBODY-BASED PLASMA ASSAYS FOR FIBRIN(OGEN) 
AND DERIVATIVES, AND THEIR CLINICAL RELEVANCE 
H. Kroneman12, W. Nieuwenhuizen3, E.A.R. Knot12 
Department of Internal Medicine Il1, University Hospital Rotterdam-Dijkzigt, Center 
for Clinical Decision Analysis', Erasmus University Rotterdam, Gaubius Institute TN03, 
Leiden, The Netherlands 
Blood, Coagulation and Fibrinolysis 1991; I :91-111 
ABSTRACT 
The haemostatic balance can basically be described as the equilibrium between fibrin 
formation (coagulation) and fibrin lysis (fibrinolysis). Therefore the status of this 
balance may be reflected by the products of these two processes. 
Until recently, the tests for assessment of fibrin(ogen) degradation products were 
performed in serum since they were based on polyclonal antibodies, which crossreact 
with fibrinogen. The use of serum introduces many artefacts and therefore the utility 
of these serum tests is limited. 
New assays have now become available which can be divided in quantitative enzyme 
immunoassays (EIA's) and semiquantitative latex agglutination assays. The new assays 
can be carried out in plasma since they use highly specific monoclonal antibodies, the 
majority of which do not crossreact with fibrinogen. This makes it possible to avoid the 
serum artefacts. Funhermore, these plasma assays can discriminate between degradation 
products of fibrin and those of fibrinogen (FbDP and FgDP, respectively). 
The possible clinical utility of the new assays is discussed on the basis of literature data 
on the following clinical states: deep venous thrombosis (DVT) and pulmonary 
embolism, liver disease and liver transplantation, sickle cell disease, renal diseases, 
pregnancy and preeclampsia, disseminated intravascular coagulation (DIC), malignancy, 
coronary artery disease and thrombolytic therapy. Fibrinolysis appears to be 
accompanied by fibrinogenolysis. Detection offibrin(ogen) derivatives may be used to 
rule out DVT; to monitor efficacy of anticoagulant treatment for DVT or DIC, and 
reflects severity of renal disease but not renal function. High levels of FgDP's were 
found during onhotopic liver transplantation and thrombolytic therapy. Fibrin(ogen) 
degradation products can not be used to predict reperfusion following thrombolytic 
therapy. The fibrinolytic system remained active during normal and complicated 
pregnancy and in patients with malignancies. 
The new assays provide valuable information on fibrin( ogen)olysis in several diseases. 
More information on the haemostatic balance may be obtained by using these new 
assays for fibrin(ogen)olysis products in combination with assays for coagulation 
products. 
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INTRODUCTION 
The haemostatic balance can be described as the equilibrium between the two opposing 
processes coagulation and fibrinolysis. Coagulation will lead to fibrin formation, and 
the formed fibrin will be lysed by fibrinolysis. It is conceivable that disturbances in the 
haemostatic balance will be reflected by the concentrations and composition of the 
products of the two processes i.e. fibrin(ogen) derivatives which can be used as 
molecular markers of the status of the haemostatic balance. 
The measurement of levels of fibrin( ogen) degradation products has been practiced for 
at least two decades using a variety of procedures. 1 Several clinical disorders have been 
described that are associated with abnormalities in the degradation of fibrin( ogen). 
However. since no clinically useful test was available that could measure the 
degradation products of fibrinogen specifically, it was not possible to make a distinction 
between the degradation products of fibrin and fibrinogen (FbOP's and FgOP's 
respectively). 
Elevated levels of fibrin(ogen) degradation products (FOP's) have been detected in 
serum in the past and were found in venous thromboembolism and diffuse intravascular 
coagulation, but also following trauma, surgery. infection. malignancy and sickle cell 
anaemia-'·'·"·" It has been postulated that increased FOP levels may be of value in 
confirming the diagnosis of diseases characterized by an activated coagulation system 
and that normal FOP levels could exclude the diagnosis-'.!' The observation of an initial 
rise and subsequent fall of levels of fibrin( ogen) degradation products following 
thrombolytic therapy in patients with acute myocardial infarction, suggested that 
measurement of fibrin(ogen) degradation products could also be used to monitor the 
effect of thrombolytic therapy 15•16 
In patient management, a test for the detection of a disease characterized by an 
activated coagulation system is clinically useful when it can rule out (suspected) 
patients who do not have the disease (specificity= true negative rate= number of 
patients without the disease with a normal test divided by the number of people without 
the disease) and does conl1rm diagnosis in case the disease is present (sensitivity= true 
positive rate= number of patients with the disease with an abnormal test divided by the 
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number of patients with the disease). However, due to a lack of specificity and 
accuracy of the serum assays for FDP assessment, the issue of measuring FDP levels 
as markers for pathologic conditions has been confounded. Most of these assays could 
only be performed in serum samples since they were based on polyclonal antibodies 
to fibrin(ogen) and derivatives. As will be pointed out below, the use of serum samples 
is unreliable since it introduces many artefacts. Also, polyclonal antibody-based serum 
assays could not discriminate between degradation products of fibrinogen and those of 
fibrin. Data based on such serum assays should therefore be interpreted with caution. 
New techniques have recently become available for the quantitative determination of 
fibrin (FbDP) - as well of fibrinogen degradation products (FgDP). These new assays 
are performed on plasma samples (thus avoiding the well known serum artefacts) and 
are based on monoclonal antibodies. Since a specific test has now become available to 
determine degradation products of fibrinogen, these assays permit a separate 
quantification of the extent lysis of fibrin (secondary fibrinolysis) and that of fibrinogen 
(primary fibrinolysis or fibrinogenolysis). 
Application of the new ·assays as well their possibility to discriminate between 
fibrinogen-and fibrin degradation products may be of value in the diagnosis of a disease 
and the recognition of an altered state of haemostatic function, e.g. a state of strong 
fibrinogenolysis that may be associated with an increased risk of bleeding. This may 
have implications for the subsequent therapeutical approach in the clinical condition 
under study. 
The clinical experience with the new assays is steadily growing. and it is becoming 
more and more clear that the current diagnostic concepts may have to be adapted, since 
they are based on the questionable serum assays. This review article describes the 
formation of fibrin(ogen) .md their derivatives. the available plasma assays for their 
assessment and evaluates the clinical utility of the new assays in studies described until 
now. 
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FORMATION OF FIBRIN(OGEN) DERIVATIVES 
a. Fibrin formation 
Fibrinogen is a symmetrical glycoprotein with a molecular weight of 340,000 daltons. 
It is composed of six polypeptide chains: 2Aa-, 2 BB- and 2 y-chains, which are kept 
together by disulphide bonds. In electron microscopic images of fibrinogen a central 
nodule and two larger outer nodules are observed. n The central nodule contains the 
amino-terminal ends of all six polypeptide chains and is designated as the E-domain. 
The more distal nodules are designated as the D-domains and contain the middle and 
carboxyl-terminal parts of the Aa-, BB and y-chains. The D-domains are connected to 
theE-domain by relatively thin connecting structures. When the coagulation system is 
activated, thrombin is formed. Thrombin will conven the soluble fibrinogen to the 
insoluble fibrin through a series of intermediate products."' This process is initiated by 
the cleavage of the fibrinopeptides A (FpA) from the amino-terminal ends of the Aa-
chains (in the centralE-domain). The formed product is fibrin I (or desAA fibrin). The 
Aa-chains after release of FpA, are designated as a-chains. The new amino-terminal 
ends of the a-chains are able to interact with complementary sites in fibrinogen and in 
other fibrin I molecules. At low concentrations fibrin I will be kept in solution by 
complexation with fibrinogen. This is known as soluble fibrin. 18~1 At higher 
concentrations the fibrin I molecules will polymerise to a macroscopic gel 32, in which 
the subunits will be crosslinked by coagulation factor XII! in the presence of Ca2• •20 
Simultaneously, but more slowly, thrombin can also release the fibrinopeptides B (FpB) 
from the BB-chains (in the central E-domain), which results in fibrin !I (desAABB-
fibrin) formation. Like fibrin I, fibrin II can aggregate to form a gel, in which the 
subunits are crosslinked by factor Xlll in the presence of Ca2'. 
The individual steps are summarized in Figure 1. 
It is conceivable that fibrin formation, which is not counterbalanced by fibrin lysis, will 
result in increased blood levels of soluble fibrin. Soluble fibrin could thus be an 
indicator of an impending thrombotic event. 
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Figure 1. Possible pathways of the formation of fibrin and fibrinogen derivatives. 
b. Formation of fibrinogen degradation products (fibrinogenolysis) 
Activation of the fibrinolytic system will result in plasmin formation. Plasmin is not a 
fibrin-specific protease. however. and it may also degrade fibrinogen. 
The carboxyl-terminal ends of the fibrinogen Au-chains (in the distal D-domains) are 
highly sensitive to proteolytic activity. In normal healthy individuals, fibrinogen occurs 
in three main molecular forms: A high molecular weight form (HMW) in which both 
Au chains are intact; a low molecular weight form (LMW) with one slightly shonened 
Au-chain and a form with both Au-chains partly proteolysed (LMW').''-35 All three 
forms are clottable. The LMW'-form comprises only 4% of all clottable fibrinogen in 
a normal individual. The LMW and LMW' forms possibly result from plasmin activity. 
It is conceivable that changes in the blood proteolytic activity will first be reflected in 
an increase in the LMW' !HMW ratio. 
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When the plasmin digestion of fibrinogen proceeds further, a product is formed, in 
which only about 30% of the length of both Au-chains is left. These products still 
contain the FpA, and are called fragments X. Subsequently fragment X is cleaved into 
one fragment Y and one D-fragment. Fragment Y is composed of the centralE-domain 
of fibrinogen (with the FpA) and one D-domain. Eventually, fragment Y will be 
cleaved in one E- and one D-fragment. Thus one fibrinogen molecule will eventually 
yield one fragment E, and two fragments D, in full agreement with the three nodules 
seen in the electron microscopic images. 
c. Formation of fibrin degradation products 
The degradation by plasmin of the different forms of fibrin mentioned above, proceeds 
through intermediate products analogous to those described for fibrinogen. The reason 
for this appears to be that plasmin follows the same interdomainal cleavage pattern in 
fibrin as in fibrinogen. 
Non-crosslinked fibrin I will be cleaved subsequently into fragments X1, Y1, D and E1; 
non-crosslinked fibrin ll will yield X11, Y 11, D and E11• The suffixes I and ll denote the 
absence of FpA, and of FpA and FpB. respectively. 
The crosslinked fibrins I and II consist of very long polymers of fibrin I and II. in 
which the subunits are crosslinked by isopeptide bonds. The subunits in these polymers 
will be proteolysed by plasmin in a random fashion. This will result in smaller (soluble) 
fragments of the original polymers. with a range of molecular weights?'·" These are 
collectively designated as X-oligomers."-'1.36 Upon prolonged digestion by plasmin 
these X-oligomers will be convened to fragments D-dimer i.e. two covalently bound 
D-domains 20'36 and fragments E. 
d. Molecular features of different fibrin(ogen) derivatives 
On the basis of the brief description of the various fibrin(ogen) derivatives in the 
preceding paragraphs. several molecular features can be recognized, which discriminate 
one (group of) fibrin(ogen) derivative(s) from another. These are summarized in Table 
L 
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Table 1 Molecular characteristics of fibrinogen and some fibrin(ogen) 
derivatives. 
fibrin(ogen) derivative 
HMW-Iibrinogen 
soluble fibrin/non-crosslinked 
crosslinked fibrin 
molecular characteristics 
carboxyl-terminals Acx-chains intact; 
contains FpA; no crosslinks 
contains no FpA or crosslinks; new 
amino-terminus in a-chains 
contains no FpA; contains cross-
links; new ex-chains amino-terminus 
fibrinogen degradation products (FgOP) contains FpA; altered conformation 
as compared with fibrinogen (neo-
non-crosslinked fibrin degradation 
products (FbDP) 
crosslinked fibrin degradation 
products (XL-FbDP) 
epitopes) 
contain no FpA; altered conformation 
as compared with fibrin (nee-
epitopes) 
contain no FpA; altered conformation 
as compared with fibrin ( neo-
epitopes); contain crosslinks. 
Table I Molecular characrerisctics of fibrinogen and some fibrin(ogen) derivatives 
As will be shown below n~w monoclonal antibody-based assays are mostly based on 
the specific recognition of these molecular features. 
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ASSAYS FOR FIBRINOGEN AND ITS DERIVATIVES 
Serum samples should not be used 
Even in case of a disease, the blood concentrations of fibrin(ogen) derivatives will be 
low, as compared with the fibrinogen concentration i.e. in the microgram/ml range. For 
that reason sensitive immunological methods such as enzyme immunoassays (EIA) or 
latex agglutination assays are required. Until relatively recently, only serum could be 
used as a sample since the available polyclonal antibodies crossreact virtually 
completely with fibrinogen. The latter had to be removed e.g. by serum preparation. 
Well-known serum assays are the Thrombo-Wellco assay and the tanned red-cell 
hemagglutination inhibition assay.37 Serum, however, is a notorious source of anefactual 
results: 
* 
* 
* 
• 
Incomplete clotting of the cross-reacting fibrinogen may occur in cases of 
dysfibrinogenemia: when a patient has been exposed to heparin 38 or when 
anticoagulant fibrinogen degradation products are present.39-41 In polyclonal 
antibody-based serum assays this will inevitably lead to too high or false-
positive results. Those can also result from partial lysis of the clot during serum 
preparation. not only in hyperfibrinolytic patients. but even in normal 
individuals. 19 
Some degradation products will coagulate ' 0•42 or become adsorbed to the 
clot."·''·" For that reason they will not be recovered in the serum and false-
negative or too low results may be found. 
During serum preparation fibrinogen degradation products will loose their FpA. 
As a result they can no longer be discriminated from non-crosslinked fibrin 
degradation products, and primary fibrinogenolysis can not be detected. 
Serum can obviously not be used for the assessment of the products of ongoing 
coagulation in a patient. 
These problems inherent in the use of serum could be avoided by the use of plasma. 
Only relatively recently. with the advent of the monoclonal antibody technology, it has 
2l 
become possible to develop assays which can be performed with plasma samples and 
thus avoid the serum artefacts. 
The new assavs 
In the following paragraph a brief outline will be given of the currently available assays 
based on monoclonal antibodies, which can be performed with plasma samples. The 
fundamental change as compared with the old technology is that monoclonal antibodies 
are used. which do not react with fibrinogen (except in the assay for intact fibrinogen, 
which will be described). This allows the assessment of coagulation and 
fibrin(ogen)olysis products in the same individual sample. 
Available monoclonal antibody based plasma assays 
Enzyme immunoassays (E!A) 
All the available enzyme immunoassays are of the sandwich-type. They are based upon 
a specific monoclonal antibody absorbed to the wells of a microtitration plate. This is 
the solid phase. or capture antibody. Usually the capture antibody is directed against 
one of the molecular characteristics of a fibrin(ogen) derivative, summarized in Table 
1. In the second step, the captured fibrin(ogen) derivative is tagged with an enzyme-
labeled panspecific monoclonal antibody (or polyclonal antiserum), or with another 
enzyme-labeled monoclonal antibody with a defined specificity. The enzyme is usually 
horseradish peroxidase (HRP). 
The most relevant EIA • s described today are summarized in Table 2. As can be seen 
plasma assays are now available (or will be available soon) for intact fibrinogen; 
soluble fibrin; the total of degradation products derived from fibrinogen and fibrin; for 
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Tabla 2 Currendy described EtA's for fibrinogen and its derivates 
specificity of 
EIA specific for 
Intact fibrinogen 
soluble fibrin 
fibrin.Q.9£!.! degradation products 
(FgOP) 
X--¢ligomors 
0-.dimer 
0--dimer 
fibrin degradation 
products (FbDP) 
total of degradation products 
(TOP) of fibrin (FbDP) plus those 
of fibrinogen (FgOP) 
Capture antibody 
Intact carboxyHermlnus of Au-
chains (GS) 
now amino-terminus of fibrin a-
chain (anti-lbn-17) 
altered conformation In 
fibrin{ogon) degradation products 
(FOP-14) 
X--¢/igomers (NiBn 52) 
crosslinks In 0-dimer {DD3B6) 
mainly for 0-dimor 
altered conformation in 
fibrin(ogon) degradation products 
(FDP-14) 
altered conformation in 
fibrin{ogon) degradation products 
(FOP-14) 
•.u.l from Organon Teknika, Turnhout, Belgium 
tagging antibody 
amino-terminus of Aa-cha!n, Incl. 
FpA (VIS) 
non-specllic (pofyc!onal) 
amino-terminus of Aa-chain (incl. 
FpA) (Y18) 
X--¢1igomers (NiBn 178) 
panspecific anti-0 monoclonal 
antibody 
panspecilic antibody 
monoclonal antibody against D of 
non-crosslinked fibrin and 0-
dimer (OD-13) 
mixture of two monoctonals 
(Y18 + DD-13) {see above) 
l Maboo, Brisbano, Australia, and America! Diagoostica, Greenwich, USA. 
Diagnoslica Stage, Asni9res, France: Boehringer Mannhelm, Mannheim, FRG 
remarks 
Commercial!y available 
soon\ Duration of assay onfy 45 
minutes 
Commercially availablo2• Duration 
c>l assay only 45 minutes 
Commercial!y available,. 
Commercially available~. 
Commercially available1• Duration 
of assay only 45 minutes 
Commercially available'. Duration 
of assay only 45 minutes 
referoooos 
----
21,22 
23,24,25 
26,27 
10,11 ~ 
28,29 
30,27 
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early fibrin degradation products (X-oligomers); for late fibrin degradation products, 
and for fibrinogen degradation products. With this panel of E!A' s it is possible to draw 
conclusions about the status of the haemostatic balance in much detail.45 
Agglutination assays 
Apart from the quantitative EIA's described above, also semiquantitative latex 
agglutination assays are available for use in plasma. These are: 
* An assay for D-dimer, based on DD3B6 28.29 monoclonal antibody (see table) 
and available form MabCo, Brisbane, Australia; from American Diagnostica, 
Greenwich, USA and from Ortho Diagnostics. Beerse, Belgium. 
* 
* 
A D-dimer test from Diagnostica Stago. Asnieres, France; from Boehringer 
Mannheim. Mannheim, FRG and from Organon Teknika, Turnhout, Belgium. 
A D-dimer test reported by Soria 46• which is not commercially available. 
CLINICAL STUDIES WITH THE NEW ASSAYS 
The clinical experience of the new assays is rapidly growing and degradation products 
of fibrin and fibrinogen were measured in plasma samples of patients with several 
different diseases. Theoretically, clinical disorders associated with elevated fibrin(ogen) 
degradation products. as assessed by the new assays. can be divided in three different 
categories: 
A) diseases in which the process of primary fibrinolysis (fibrinogenolysis) dominates, 
resulting in elevated levels of FgDP's; 
B) disorders with a pronounced increase of FbDP levels. indicative for the 
occurrence of secondary fibrinolysis: and 
C) clinical states characterized by an enhancement of both fibrinogenolysis and 
fibrinolysis. 
Most diseases with increas~ levels offibrin(ogen) degradation products can be placed 
in this last category and we prefer to discuss the different diseases separately. 
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Deep venous thrombosis and pulmonary embolism 
The diagnosis of deep venous thrombosis (DVT) based on clinical symptoms only, is 
missed in 50% of the cases 47·" Therefore it should be confirmed by objective methods 
and of these, ascending venography is considered as a golden standard. There is a need 
for non-invasive tests like impedance plethysmography, echography and also laboratory 
tests. A simple screening test that selects patients for further diagnostic procedures can 
be clinically useful. Efficacy of heparin treatment for DVT is often evaluated by 
repeated venography. Since this procedure is time consuming, expensive and not 
without risks, a method is needed that could replace this invasive technique. Using the 
new assays, the levels of fibrin(ogen) degradations products levels were measured in 
plasma to determine their role in both diagnosis and evaluation of treaunent for DVT. 
Using a semiquantitative latex assay for detection of plasma D-dimer it was possible 
to make a clear distinction between normal subjects and hospitalized patients with DVT 
confirmed by venography." In that study, all patients with confirmed DVT had plasma 
D-dimer levels above the r.oinimal detectable concentration of 250 ng/ml. None of the 
healthy controls reached these levels. However, another study showed that plasma D-
dimer levels of hospitalized patients with DVT (the authors do not mention how the 
diagnosis was confirmed) showed some overlap (<5%) with those of healthy 
volunteers. 50 In both studies. the correlation between plasma D-dimer levels assayed by 
the semiquantitative latex assay and the quantitative EIA was highly significant 
(r=0.83.P<0.001 ' 9 ; r=0.82. P<O.OOOl 50) The plasma D-dimer latex assay was also 
applied to a population consisting of hospitalized-and outpatients suspected for DVT.51 
In this study the sensitivity and specificity of the latex assay (cut-off value for test 
positivity: 200 ng/ml) for DVT were 73% and 69% respectively. The test results were 
not separately determined in the in- and outpatient groups. The diagnosis of DVT was 
made by ascending venography. To be useful as a screening test for DVT, the latex D-
dimer assay must allow to discriminate in the group of patients clinically suspected for 
DVT those who have DVT from those who don't. This can be determined by 
calculating the predictive value of a positive or negative test result, meaning the 
probability of having or not having the disease. 
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In that study 51 with a prevalence of DVT of 72%, the positive and negative predictive 
value were 63% and 78% respectively. In another study two different D-dimer latex 
assays were used in hospitalized -and outpatients suspected for DVT 52 The prevalence 
of DVT, as assessed by venography was 65%. One of the assays using a cut-off value 
of 500 ng/ml had a sensitivity of 76%, a specificity of 87% and the positive and 
negative predictive values were 80% and 85% respectively. The other latex assay (cut-
off value 200 ng/ml) had a sensitivity, specificity and a positive and negative predictive 
values of 60%, 97%, 92% and 80% respectively. The test results were calculated for 
the whole population and not for the subgroups of hospitalized patients and outpatients 
separately. Similar observations were reported by others." 
The above studies mentioned above clearly demonstrate that D-dimer levels, as 
determined by the latex agglutination assay, cannot be used to exclude the diagnosis 
DVT. Using this assay as screening test for DVT the diagnosis will be missed in 15%-
22% of the patients 51 .s2 which is an unacceptably high percentage. Based on these 
grounds the conclusion is justified that the D-dimer latex assay is unsuitable as a 
screening test for DVT. 
Using a D-dimer EIA, it was shown the level of plasma D-dimer was elevated in 
hospitalized patients with DVT, confirmed by venography."·" No overlap was 
demonstrated with the D-dimer levels in normal healthy controls (cut-offvalue for test 
positivity:200 ng/ml). 
In a population consisted of hospitalized patients suspected for DVT, the D-dimer EIA 
had a sensitivity and specificity for DVT of I 00% and 23% respectively, as assessed 
by venography." The used cut-off value for test positivity was 250 ng/ml. The 
prevalence for DVT was 52% and the negative predictive value was !00%. Similar 
observations were made in other studies using the D-dimer EIA 's.51 .52 The studies 
mentioned above show that the diagnosis of DVT can be ruled out in hospitalized 
patients with clinically suspected DVT in case of normal D-dimer levels, as determined 
by the quantitative D-dimer EIA. As a consequence ascending venography could have 
been avoided in these patients. 
The ElA for plasma D-dimer was also applied to an outpatient population with 
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clinically suspected DVT.5" The sensitivity and specificity of the D-dimer ElA (cut-off 
value:200 ng/ml) for DVT were 100% and 61% respectively. as evidenced by 
venography. In that population with a prevalence for DVT of 35%. the predictive value 
of a positive test was 61% and the negative predictive value was 100%.56 Similar 
results were found in other studies.51 ·52 One of these studies showed that the negative 
predictive value declined from 100% to 93% when the cut-off value for test positivity 
was raised from 200 ng/ml to 500 ng/ml.52 Another study reported a negative predictive 
value of 98% using a cut-off value of 200 ng/ml.53 These studies. which were 
performed in outpatients. confirm the observations obtained on hospitalized patients. 
that normal D-dimer levels. determined by EIA. can be used to exclude the diagnosis 
in patients with suspected DVT. Based on these results it was suggested that the D-
dimer EIA could be used as a screening test for DVT and that ascending venography 
can be avoided in patients with D-dimer levels below the cut-off point for test 
positivity.53·54 In clinical practice this would be a great advantage. However, the 
predictive value of a test can dramatically be affected by the prevalence of the disease 
in the studied population i.e. the positive predictive value decreases with the prevalence. 
but the negative predictive value may rise simultaneously. It is not advisable to apply 
the predictive value of a test obtained in one population to another without knowing the 
prevalences in these populations. The utility of the EIA for D-dimer as a screening test 
for DVT in a certain population can be determined by studying the costs-effectiveness 
in relation to the prevalence of DVT in that population. 
With a specific EIA for fibrin degradation products (FbDP"s). increased plasma levels 
of FbDP"s were demonstrated in patients with DVT relative to FbDP levels in plasma 
of healthy controls.30~'·" Patients with DVT had also increased levels of fibrinogen 
degradation products (FgDP). although the latter were less elevated than the FbDP"s.57 
This suggests that secondary fibrinolysis was accompanied by fibrinogenolysis. 
Applied to outpatients. clinically suspected for DVT. the EIA for FbDP (cur-off value 
270 ng/ml) had a sensitivity of 92% and a specificity of 20% for the diagnosis of DVT. 
as determined by impedance plethysmography (!PG).57 A second lPG examination was 
performed after one week when the first lPG examination was negative. In the same 
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study, the sensitivities of the E!A for FgDP (cut-off value: 250 ng/ml) and the EIA for 
TDP (cut-off value: 590 ng/ml) were 90% and 95% respectively. The specificities were 
25% and 16% respectively. In this population with a prevalence of DVT of 25%, the 
negative predictive values of the ElA's for TDP, FbDP and FgDP were 90%, 87% and 
88% respectively. The test characteristics of the EIA's were better, if compared to the 
results of the first lPG examination only, e.g. the sensitivity and the negative predictive 
value of the E!A for TDP were 98% and 97% respectively. The utility of these EIA's 
as screening test for DVT can be determined in the same way as described above. 
Until now, no studies have. been described that investigated the test characteristics of 
the EIA's for TDP. FbDP and FgDP in hospitalized patients suspected for DVT. 
All patients with pulmonary embolism (PE), confirmed by lung perfusion scanning had 
increased plasma levels of D-dimer when compared to the levels of D-dimer in normal 
controls, as detected by ElA55 This finding was confirmed in another study where all 
patients with PE, as assessed by pulmonary angiography, had elevated levels of plasma 
D-dimer (above the normal value in healthy volunteers of 130 ± 65 ng/ml) in contrast 
to the normal level of D-dimer that was observed in one patient in whom PE could be 
excluded.60 The same results were found using an EIA, specific for X-oligomers (cross-
linked fibrin degradation products with a high molecular weight). 61 
With regard to daily clinical practice it is important to know whether the level of 
plasma D-dimer can predict the presence or absence of PE in a population of patients 
suspected for PE. By examination of patients suspected for PE using an EIA for D-
dimer, it was demonstrated that a high suspicion of PE on the basis of a lung scan 
corresponded to D-dimer levels above 500 ng/ml in all patients, but in case the scan 
was inconclusive, a D-dimer value below 500 ng/ml could not exclude PE.62 
Plasma of patients suspecred for PE was also assayed with an E!A that recognizes 
cross-linked D-dimer fragments and related high molecular weight fibrin derivatives 
containing D-dimer (XDP's).63 Using a cut-off value for test positivity of 145 ng/ml, 
the sensitivity and specificity of that EIA for the diagnosis of PE were 89% and 44% 
respectively, as evidenced by lung perfusion scanning. In that population with a DVT 
prevalence of 38%, the predictive value of a negative test was 92%. This study 
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demonstrates that the diagnosis PEcan not be excluded in patients clinically suspected 
for PE with normal levels of XDP, as assessed by this XDP EIA. Since the diagnosis 
of this potentially life treathening disease will be underestimated in 8% of the cases 63 
it can be concluded that the EIA for XDP assessment alone, can not be used as a 
screening test for PE in clinically suspected patients. 
Similar observations were found with the semiquantitative latex agglutination assays 
for D-dimer. An increased plasma D-dimer level was demonstrated in 98% of patients 
with PE confirmed by lungscan but in none of the healthy controls (cut-off level for 
test positivity: 250 ng/ml).'9 The observed overlap between D-dimer levels in patients 
with PE and normal controls was confirmed by others using a cut-off level for test 
positivity of320 ng/ml. 50 Another study showed that 54% of the patients with clinically 
suspected PE. who had a high probability on lungscan, had a negative latex 
agglutination assay (cut-off value: 500 ng/ml).64 This supports the finding obtained by 
application of the D-dimer EIA "s that it not possible to exclude the diagnosis PE in 
patients with clinically suspected PE on the basis of a normal D-dimer level alone. In 
these patients. further diagnostic procedures are indicated. 
The possibility to use plasma levels of FbDP or D-dimer, as markers of secondary 
fibrinolysis to monitor thrombolytic and heparin therapy in patients with venous 
thromboembolism has been investigated using EIA 's.58•59•65 It was demonstrated that a 
change in plasma FbDP level was reflected in a change of thrombus size during heparin 
treatment. This was assessed by repeated venography based on Marder scores. A fall 
in FbDP level was accompanied by thrombus regression. but when the FbDP level 
remained constant during treatment. no reduction of thrombus size could be observed. 58 
In that study a good correlation (r=0.79) was found between high initial plasma FbDP's 
and thrombus size. These results suggest that FbDP detection by EIA is useful in the 
monitoring of heparin treatment. More data are needed to confirm these findings. 
Thrombolytic therapy with streptokinase (SK) or urokinase (UK) was followed by an 
increase of FbDP's during the first 12 hours of treatment.59•65 Following SK or UK 
therapy it was demonstrared that low initial plasma FbDP level predicted a poor 
decrease in thrombus size, but the changes ofFbDP levels were not correlated (r=0.21) 
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to the changes in thrombus size. as assessed by repeated venography." This was 
confirmed by others65 However, an increase of FbDP levels is no evidence for lysis of 
the thrombus, since elevated levels of FbDP were also found in normal healthy 
volunteers following t-PA infusion.66 
Liver disease and liver transplantation 
Patients with chronic liver disease often develop localized bleeding episodes (ruptured 
esophageal varix, haemorrhagic gastritis 67) that tend to massive haemorrhage and are 
an important cause of death in these patients."·" The disturbance of blood coagulation 
is complex in patients with liver cirrhosis. It has been hypothesized that liver cirrhosis 
is frequently complicated by disseminated intravascular coagulation (DIC) and that 
consumption coagulopathy due to DIC plays a role in the pathogenesis of haemorrhage 
in patients with liver cirrhusis.70.75 However, this view is not accepted by all.n.76·77 
A number of studies reponed that fibrinolysis is enhanced in patients with liver 
disease-''·" This was evidenced by the observation of increased plasma t-PA antigen 
levels presumably due to ' diminished hepatic clearance of t-PA 81 •84 and decreased 
levels of a,-antiplasmin probably due to a decrease in synthesis capacity of the affected 
liver.79•80 
The new plasma assays have been applied to patients with liver cirrhosis and patients 
undergoing liver transplantation. Using an ElA for intact fibrinogen (HMW + LMW) 
in patients with liver cirrhosis, classified according to the Child-Pugh classification, it 
was shown that the level of intact fibrinogen decreased with increasing severity of the 
disease, and was lowest in Child C."' The FgDP levels. as detected by EIA, were only 
slightly elevated compared to the level in normal controls and did not correlate to the 
severity of the disease. 
This either suggests that extensive fibrinogenolysis is not a common feature in patients 
with liver cirrhosis and the decreased levels of intact fibrinogen can be explained by 
a lowered synthetic capacity of the diseased liver or that fibrinogen beyond the stage 
of LMW' formation does not occur (see above). Further it was shown in that study that 
both the FbDP and TDP levels were elevated and showed a positive correlation with 
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the severity of the disease. This indicates that the process of secondary fibrinolysis is 
more active in patients with an advanced stage of liver cirrhosis. 
The observation of increased FbDP levels, as detected by EIA, in patients with liver 
cirrhosis was confirmed in another study.86 These findings may be indicative of the 
presence of a hypercoagulable state, although a failure of the clearance of fibrin 
degradation products by the damaged liver can not be excluded. Further studies are 
needed to answer this clearance question and to determine whether increased FbDP 
levels are correlated with organ failure due to fibrin deposition. 
Using a semiquantitative D-dimer latex assay in patients with liver cirrhosis classified 
according to Child and Pugh it was shown that the level of D-dimer was elevated (p 
< 0.001) in patients with Child C classification as compared to the D-dimer levels in 
patients with Child A and B.87 In that study. no significant difference was observed 
between the D-dimer level in patients with Child A and B classification. Elevated 
plasma levels of D-dimer, detected by latex assay, were also demonstrated in patients 
with liver disease (the authors did not specify the disease) and increased when DIC was 
superimposed.88 These latter studies, using semiquantitative assays. suppon the previous 
conclusion based on EIA's that secondary fibrinolysis is more pronounced in patients 
with advanced liver cirrhosis. 
Orthotopic liver transplantation (OLT) is accompanied by serious bleeding 
complications 89 •90 presumably caused by a hyperfibrinolytic state 91 •92 or secondary to 
diffuse intravascular coagulation (DIC).93' 95 Measurement of plasma levels of 
fibrin(ogen) degradation products by EIA's, showed that the levels of FbDP's and 
FgDP's increased significantly relative to pre-operative values, at the end of the 
anhepatic phase during OLT. The rise of FgDP levels was, however, less than the rise 
of FbDP levels.96 In that study. FgDP levels reached a maximum shortly after 
recirculation of the gf'<~ft and just before the FbDP peale Similar findings were reponed 
by others86•97 Using a D-dimer EIA. it was demonstrated that plasma D-dimer level also 
10se in the anhepatic phase and following hepatic revascularization during OLT.9'-100 
In conclusion, the rise in FgDP level clearly demonstrates the occurrence of 
fibrinogenolysis during Ol.T, which may considerably contribute to the disturbance of 
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the haemostatic function. It can be concluded that OL T is accompanied by both 
hyperfibrinolysis and an activated state of coagulation. The observed peaks of the FbDP 
and FgDP levels in the early post anhepatic phase correspond to the clinical picture of 
increased bleeding tendency during that period. Whether the increase in the levels of 
fibrin( ogen) degradation products are indicative for the intra-operative blood loss and 
can be used to identify patients with active fibrinolysis with an increased risk of life 
treathening haemorrhage. remains to be determined. 
During auxiliary partial liver transplantation (APLT) ElA • s were also used to measure 
fibrin(ogen) degradation products. It was shown that FgDP, as detected by an E!A, was 
elevated during the operation (maximum level: 1.0 ug/ml) but was no longer detectable 
during the first day after the operation, whereas TDP and FbDP showed no abrupt 
changes during the operation. FbDP, however, remained detectable until 25 days after 
transplantation. 101 These data are based on measurements in one patient and more 
studies are needed to confirm these findings. 
Sickle cell disease 
The primary biochemical lesion in sickle cell disease is an alteration of the structure 
in the B chain of the haemoglobin resulting in the so called haemoglobin S. Red cells 
containing haemoglobin S at a high concentration become eventually irreversibly 
sickled. and this has two main effects. Firstly it shortens the survival of the erythrocytes 
and secondly the viscosity of the blood increases because of the formation of 
aggregates of the sickled cells which may result in stasis and hence occlusion of the 
microvasculature. which is experienced as painful by many patients. 
It is not clear whether activation of the coagulation system contributes to the vasa-
occlusive crisis in patients with sickle cell disease. Several observations suggest that 
enhancement of coagulatic'n with formation of fibrin may play a role.'·102 Fibrin has 
been detected in vessels ocduded by sickle cells. 103 During steady state, the fibrin( ogen) 
fragment E level was elevated' Fibrinogen survival is shorter than normal in the steady 
state of the disease, and is further shortened during painful crisis. 1"' Many coagulation 
laboratory tests show abnormalities during painful crisis 105•106 but no test is available 
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that clearly detects the occurrence of vase-occlusive crisis. Fibrin degradation products 
were measured in plasma of patients with sickle cell disease during steady state and 
painful crisis as markers of fibrinolytic activity. 
Using a semiquantitative D-dimer latex assay with a minimum detectable concentration 
I ug/ml. it was demonstrated, that 10% of the patients with sickle cell disease who 
were asymptomatic, had elevated D-dimer levels as compared to normal healthy 
controls.107 The same study also showed that 97% of the hospitalized symptomatic 
patients during painful crisis had elevated D-dimer levels, but D-dimer was not 
detectable in plasma samples of hospitalized patients that had become asymptomatic 
following a painful crisis. With respect to the clinical status of the patients (assessed 
by history and physical examination) a significant correlation (p < 0.001) between 
disease activity and the presence of D-dimer plasma level was noticed. D-dimer was 
detectable in only 10% of the steady state (asymptomatic) patients, indicating that the 
fibrinolytic activity is more pronounced during painful crisis. 
Using a D-dimer E!A, the observation of elevated D-dimer levels during painful crisis 
was confirmed in another study .108 1n that study, significant differences (p<O.OOI) in D-
Dimer levels were noticed between healthy controls. asymptomatic patients with sickle 
cell disease during steady state and symptomatic patients during painful crisis. In 93% 
of the cases, D-dimer plasma levels in the asymptomatic patients during steady state 
were above the upper limit of the level of healthy individuals (129 ng!ml). This is 
higher than the 10% in the previously mentioned study 107 and can be explained by the 
fact that the ElA is more sensitive for the detection of low grade activation of 
coagulation and reactive fibrinolysis than the latex agglutination assay. 
Plasma of patients with sickle cell disease has not yet been assayed by EIA's for TOP, 
FbDP and FgDP. 
Based on the aforementioned data, it can be concluded that application of the new 
assays has demonstrated that fibrin formation and subsequent lysis is not an exclusive 
feature of the vase-occlusive crisis, but is also present during steady state. Whether 
measurements of plasma levels of fibrin( ogen) degradation products are useful to detect 
the occurrence of vase-occlusive crises or other complications in patients with sickle 
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cell disease may be assessed by studying the predictive value of the assays in the 
clinically relevant population. 
Pregnancy and Cpre)eclampsia 
During preeclampsia, a decrease in platelet count, anti-thrombin III (AT-lli), 
plasminogen and <X;,-antiplasmin is observed-"'·''' However, none of these laboratory 
data reflects coagulation abnormalities accompanying preeclampsia satisfactorily_uz.uJ 
Therefore these tests are not useful to monitor the occurrence of preeclampsia in high 
risk groups. It has been suggested that measurements of levels of fibrin( ogen) 
degradation products may be of value to diagnose (pre)eclampsia since it was observed 
that toxemia of pregnancy may be developing when these levels increase.11'-116 
However. the assays were performed in serum. 
Plasma of women with normal, uncomplicated pregnancy and of women with 
pregnancy complicated by preeclampsia was assayed for D-dimer and fibrin( ogen) 
degradation products, using semiquantitative latex agglutination tests. 117. 119 Plasma 
samples of women with normal pregnancy were negative for fibrin( ogen) degradation 
products in 98%-100% of the cases '"·"'and only 5% of the women showed detectable 
levels of plasma D-dimer (cut-off value: 200 ng/ml)."' In that study the increase of D-
dimer showed a positive correlation (r=0.64) with the fibrin(ogen) degradation products 
levels. 
During the preeclamptic state. elevated plasma levels of fibrin(ogen) degradation 
products have been observed.'"·'" In 38,7% of the preeclamptic women elevated 
Plasma D-dimer levels were observed. in contrast to the healthy pregnant women in 
whom no elevations were observed (detection limit 2 J.Lg/ml).117 The D-dimer positive 
women had a higher blood pressure (systolic and diastolic), more proteinuria and 
abnormal liver function rests, a higher serum creatin and blood urea nitrogen than 
preeclamptic women with normal D-dimer levels. In addition the D-dimer positive 
women showed a higher risk for prematurity and low binh weight. It was concluded 
that the semiquantitative latex agglutination assay for D-dimer may be a useful test to 
screen preeclamptic women in order to define a subgroup with a high risk for 
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coagulation abnormalities. 
Also quantitative E!A's were used to study plasma levels of fibrin(ogen) degradation 
products in women with normal and preeclamptic pregnancy_61.1I9-122 In women with 
normal pregnancy the plasma levels ofTDP, FbDP, FgDP and D-Dimer were elevated 
as compared with a control group of healthy non-pregnant women, and especially 
increased during the last nimester of pregnancy.119-123 
This is in contrast with the findings obtained with the Thrombo-Wellco serum test that 
detects FOP. At no time during normal pregnancy significant increases of the FDP 
levels could be demonstrated. 120 This may be explained by the fact that the serum assay 
is less sensitive than the EIA, or be an artefact due to serum preparation (see above). 
Using an EIA for detection of cross-linked fibrin degradation products (X-oligomers), 
it was found that all women with clinically diagnosed preeclampsia had elevated plasma 
levels of X-oligomers, and showed no overlap with those of women with uncomplicated 
pregnancy. 61 
Despite a number of studies that reports a depressed fibrinolytic activity during 
pregnancy 124- 126, the studies mentioned above using EIA's, demonstrate an increase of 
plasma levels of fibrin degradation products during normal and complicated pregnancy. 
This suggests that the fibrinolytic activity is not necessarily impaired during pregnancy. 
Detection of plasma fibrin(ogen) degradation products by EIA's are a useful aid in the 
early diagnosis of preeclampsia and may help to formulate therapeutic action to prevent 
a full blown expression of this condition. 
Renal diseases 
The role of hemostatic disorders in the pathogenesis of renal vascular and glomerular 
diseases is not fully understood. 
Glomerular fibrin deposition is observed in many cases of glomerulonephritis and it is 
assumed to play a role in glomerular degeneration. 127•128 The presence of fibrin and 
fibrinogen (degradation products), was demonstrated immunochemically within the 
mesangium, in vascular cells and along the basement membrane in acute homograft 
rejection, postpartum renal failure and rapidly progressive glomerular nephritis.129-131 
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It has been shown that FOP, as detected by serum assays, are elevated in several renal 
diseases. 132 
Since extra-renal sites of fibrin(ogen)olysis may also be responsible for FOP elevation, 
it was suggested and confirmed that FDP levels measured in the urine would reflect 
disease activity better than FOP levels detected in serum.133-136 
An EIA was used to detect urinary fibrin( ogen) degradation products of patients with 
various types of primary and secondary chronic nephrititis.137 In that study, urinary 
Fb(g)DP levels were significantly higher (p<0.05) in patients with severe types of 
proliferative, membranous glomerulonephritis and in the active phase of SLE as 
compared to the urinary levels of normal volunteers. No correlation (the correlation 
coefficient was not given) was found between the levels of urinary Fb(g)DP and that 
of proteinuria. 
Urine of patients with glomerulonephritis characterized by active cellular crescents was 
examined using an EIA or a radioimmunoassay (RIA) specific for cross-linked fibrin 
degradation products (XLFDP's).'"-' 39 The urinary level of XLFOPs correlated weakly 
(r=0.52, p<O.OI) with the percentage of glomeruli containing cellular crescents. No 
significant correlation (r=0.6i,p=ns) was found between the levels of urinary XLFOP's 
and proteinuria.'" This may suggest lysis of fibrin(oid) material within the crescents 
or Bowman's space that was demonstrated by percutaneous renal biopsy in a majority 
of these patients. 138 
In patients with focal segmental sclerosis (FSS) or membranous nephropathy (MN), the 
urinary levels of XLFDPs correlated (r=0.73 and 0.70 for FSS and MN respectively) 
with the level of proteinuria. 139 The ratio urinary XLFDP/proteinuria was significantly 
higher (p < 0.05) in patients with glomerulonephritis (GN) with crescents than in 
patients with FFS and MN. The ratio urinary XLFDP/proteinuria was used to exclude 
that portion of urinary XLFDP that was filtered from the blood. but whether the 
detected high ratio in patients with crescents GN reflects intraglomerular fibrinolysis 
remains to be determined. 
In children with several kinds of proliferative glomerulonephritis, the demonstrated 
increased urinary levels of XLFDPs and D-dimer, as assessed by EIA's, showed no 
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correlation with the histologically detected mesangial proliferation or with the 
selectivity of proteinuria. " 0 This may suggest that lysis of intraglomerular fibrin is not 
the only source of urinary cross-linked degradation products. 
Recently it has been shown that D-dimer levels in plasma, as detected by EIA, were 
significantly elevated in non-diabetic chronic renal failure (p < 0.05), diabetic 
nephropathy (p < 0.01) and acute renal failure (p < 0.01) when compared to the D-
dimer plasma levels of healthy controls(< 220 ng!m1)."1 In that study, no correlation 
(r = -0.14) was found between plasma D-dimer and creatinin clearance. This suggests 
that detection of D-dimer in plasma by EIA can be used a marker of fibrin breakdown 
in several renal diseases and reflects disease activity. More studies are needed to 
confirm these findings. We are not aware of studies that used semiquantitative D-dimer 
assays or EIA 's for TDP. FbDP or FgDP assessment in renal disease. 
It can be concluded that EIA 's specific for the detection of urinary cross-linked fibrin 
degradation products can be used to assess activity of several renal diseases. The EIA 's 
are not suitable to assess renal function itself. since none of these assays showed 
significant correlations between fibrin degradation products and creatinin clearance. The 
origin of the observed increased levels of urinary cross-linked fibrin degradation 
products in patients with several renal diseases is not fully clear: it may result from 
filtration from the blood (because of an increased permeability of the damaged 
basement membrane). or from lysis of fibrin in the lower urinary tract or the kidney. 
In the future, the new assays performed in plasma may be applied to patients with 
homograft transplants, since in the past it has been shown that a rise in serum FDP is 
associated with impending rejection of the graft.142 
Disseminated intravascular coagulation ( D!C) 
DIC may lead to a dramatic and generalized haemostatic failure with a wide spectrum 
of clinical symptoms and is often associated with a variety of other pathological 
conditions. 12•143-148 In case of a dominant intravascular clotting process and minimal 
secondary fibrin(ogeno)lysis, DIC may present primarily as diffuse thrombosis. When 
the process of secondary fibrinolysis dominates, the clinical manifestation shifts towards 
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haemorrhage. Patients suspected of having D!C often demonstrate both clinical 
conditions simultaneously, and a laboratory test capable of discriminating between these 
two situations is needed since both clinical conditions require a different therapeutic 
approach. 
However, in patients with a clinical condition indicative of D!C, the currently used 
haemostasis parameters like prothrombine time, thrombin time, activated partial 
thromboplastin time, factor V, fibrinogen, platelet count and antithrombin Ill become 
difficult to interpret and none of these tests is specific for the diagnosis or the 
monitoring of therapy in case of D!C.149. 152 
Plasma of patients suspected of having DIC was examined by using latex assay's for 
Fibrin(ogen) degradation products.49.so.s7.147.153-1SS 
It was shown that all patients with DIC had elevated levels of plasma D-dimer as 
compared to D-dimer levels in normal healthy controls." The minimal concentration 
detectable of the used latex assay was 200 ng!ml. In that study, the diagnosis of DIC 
was based on a prolonged thrombin time. hypofibrinogenaemia, thrombocytopenia and 
elevated serum FDP's (>8 )J.g/ml) assessed by the Thrombo-Wellcotest in combination 
with clinical conditions known to be associated with DIC. This finding was confirmed 
in another study using a latex assay with a minimal detectable concentration of 250 
ng!ml." 
The latex assay was also vsed to measure plasma D-dimer levels in patients clinically 
suspected of having DIC. 15' In that study. the presence of fragment D-dimer, as 
demonstrated by immunoblotting. was used as a criterion for the diagnosis of DIC and 
all patients who had fragment D-dimer present showed clinical conditions consistent 
with the diagnosis of DIC. The sensitivity and specificity of the D-dimer latex assay 
for the diagnosis of DIC. as determined by immunoblotting, was 85% and 97% 
respectively. The prevalence was 51% and the positive and negative predictive value 
was 97% and 86% respectively. Although varying of the cut-off point may change the 
test results, the aforementioned study demonstrates, that the negative D-dimer latex 
assay alone can not be used to exclude the diagnosis of DIC in patients suspected of 
having DIC. More studies ·tre needed to confirm the test characteristics of the D-dimer 
38 
latex assay obtained in this study. D-dimer measurements by latex assay may be 
valuable in addition 10 the currently used laboratory tests in patients suspected of 
having DIC. 
Plasma of patients with DIC was also assayed by quantitative EIA's to demonstrate 
elevated levels of fibrin(ogen) degradations products.26·30.so.ss.Gt,t22.IS6-tGo using an EIA 
specific for cross-linked fi!:Jrin degradation products (XLFDP's) it was shown that all 
patients with DIC, confirmed by laboratory evidence of consumption coagulopathy and 
clinical conditions characteristically associated with DIC, had levels ofXLFDP's above 
the upper limit of 200 ng/ml that was observed in healthy controls." However, others 
detected some overlap in XLFDP levels between patients with DIC and normal healthy 
controls." Similar observations were reponed using an EIA specific for X-oligomers 
(the earliest fmgment released from cross-linked fibrin): patients with DlC had elevated 
levels of X-oligomers and showed no overlap with the levels of X-oligomers in normal 
healthy controls.'l.l 60 In these studies. the clinical diagnosis of DIC was confirmed by 
a low fibrinogen, elevated FDP in serum by latex assay, low platelet count (<10'/ml) 
and a positive ethanol geh:rion test. 
Using the D-dimer assay it was shown that all patients with DIC had elevated levels 
of D-dimer (>200 ng/ml) and no overlap was shown with those in normal healthy 
controls." However. I 0% of the hospitalized control group had elevated D-dimer 
levels.87 Plasma of patient,; was examined one week before the onset of DIC (scored 
according to Maegawa·s criteria of D!C) by D-dimer EIA. 159 Of the used laboratory 
parameters (serum FDP. D-dimer. prothrombin time, fibrinogen and platelet count), 
plasma D-dimer was the only parameter that was significantly elevated (no p value is 
given) before the onset of DIC. while the other coagulation parameters became 
significantly (p value unknown) abnormal only after the onset of DIC. This suggests 
the possibility 10 identify an early state of DlC by D-dimer measurements in which 
treatment may be started. ~nd requires further confirmation. 
Plasmas of patients with DlC were also assayed by EIA's specific for FbDP's, FgDP's 
or TDP' s. J9.26.30.l22.1S6-JS9 
Patients with a high grade DIC had increased levels of FhDP's, TOP's and FgDP's as 
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compared to the levels in healthy controls.122 In these patients, the observed level of 
FbDP was higher than the level of FgDP, suggesting that the process secondary 
fibrinolysis is dominant and is accompanied by fibrinogenolysis. 
Monitoring time dependant change of FbDP and TDP levels in plasma of patients with 
DIC showed the possibility to detect the onset of primary fibrinolysis." In that study, 
the FbDP and TDP levels were approximately equal during the first four days, 
suggesting that nearly all degradation products are derived from fibrin. During the next 
four days the levels of TDP exceeded the Fbdp levels indicating the occurrence of 
fibrinogenolysis. The justification of this conclusion may follow from another study 
where a good correlation (r=0.98) was observed between the values obtained by adding 
the levels of FbDP and FgOP, and the actually measured TDP levels in patients with 
DIC156 
The possibility to use TDP. FbOP and FgOP levels, as assessed by EIA's, for the 
monitoring of anticoagulant therapy (heparin and coumarin) and follow-up in patients 
with chronic DIC was demonstrated in another study.'" In that study, the diagnosis of 
DIC was based on the clinical picture and abnormalities in the following laboratory 
parameters: platelet count. (pro)thrombin time. factor V, fibrinogen (Clauss), FM, 
antithrombin-Ill, a,-antiplasmin and FOP in serum (Thrombo-Wellcotest). The levels 
of FbDP and FgOP changed concomitantly, FbDP being higher than FgDP. This 
indicates that both fibrinolysis and fibrinogenolysis occur. It was concluded that, of all 
used laboratory parameters, soluble fibrin, TDP, FbDP and FgDP were the most 
sensitive markers for acuve DIC and the effect of anticoagulant treatment. The 
generally accepted view that an increased level of serum FOP's is required to permit 
the diagnosis of DIC '2•36·'·,. has to be revised. 
Application ofthe EIA's showed that the secondary fibrinolysis in DIC is accompanied 
by fibrinogenolysis. More studies are needed to determine the role of fibrin(ogen) 
measurements by EIA's for the diagnosis of DIC. The EIA's for fibrin(ogen) 
degradation products have not been applied to a population suspected of having OIC 
to determine the sensitivity and specificity of these assays for the diagnosis of D!C. 
Further studies are needed to determine these test characteristics and the predictive 
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values of the assays. 
The recognition of the activity of each the two opposing processes coagulation and 
fibrinolysis is important since it may have implications for a subsequent therapeutical 
approach. Changes of plasma levels of fibrin(ogen) degradation products and soluble 
fibrin, as detected by EIA's, were longitudinally measured in a patient with acute 
promyelocytic leukemia. a condition known to be associated with DIC." The levels of 
several fibrin degradation products, such as of D-dimer, FbDP's and X-oligomers 
followed the same pattern in time. Surprisingly, an increase of these levels coincided 
with decreased levels of soluble fibrin and vice versa. This suggest that valuable 
information on the status of the haemostatic balance can be obtained by using one of 
the EIA ·s for FbDP. D-dimer or X-oligomers (as markers of fibrinolysis) in tandem 
with the soluble fibrin ElA (as a marker of coagulation). This should be confirmed in 
other studies. 
Coronary artery disease (CAD) and thrombolvtic therapy 
It is well known that thrombotic occlusion of a coronary artery is 
frequently associated with acute myocardial infarction (AMl). 161 •162 Early recanalization 
of these arteries in selected patients with AMI by fibrinolytic agents reduces short and 
long term mortality and improves left ventricular function. 163- 165 The clinical use of 
thrombolytic agents is rapidly growing and a number of treatment strategies has been 
used. 166 The success of this therapy is probably based on the induction of an extensive 
fibrinolytic state. The recognition of an increased fibrinogenolytic state is important 
since it is associated with severe bleeding complications. 167 But unfortunately, this 
cannot be detected by the standard haemostatic screening tests like the PT, the APTT 
or the bleeding time. 
The quantitative plasma assays for fibrin(ogen) degradation products were applied to 
patients with AMI in order to assess the intensity of fibrin(ogen)olysis induced by 
thrombolytic therapy and to determine the role of fibrin(ogen) degradation products as 
markers of this therapy. Increased levels of cross-linked fibrin degradation products 
(XLFDP's), detected by EIA, have been detected in patients with AM!.' 63 Elevations 
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of plasma levels of XLFDP's above 1000 ng/ml occurred within one hour in all patients 
receiving tissue-type plasminogen activator (t-PA) and in 83% of the patients treated 
with streptokinase (SK).169 Seven hours after treatment, the XLFDP levels were 
significantly elevated (p<0.01) in the t-PA treated group when compared to the 
(declining) values that were observed in the SK treated group. This indicates that the 
persistence of lysis of fibrin, as assessed by the ElA for XLFDP' s, is of longer duration 
by administration of t-PA than following SK. The response of XLFDP to SK was 
similar in the groups of patients with and without reperfusion, although in late samples 
(> 7 hours) the elevations of XLFDP tended to be greater in the reperfusion group. The 
difference. however. was statistically not significant. 
Another study showed that plasma XLFDP levels increased 6 hours after t-PA infusion 
as compared to pre-treatment values and no significant difference was observed 
between the groups that received a dosages of 150 mg and 100 mg respectively. This 
could indicate that the extents of lysis of fibrin are comparable in both groups. 170 In the 
same study. the extent of fibrinogenolysis was assessed by using an EIA for BB1-42, 
a peptide that is released when fibrinogen is degraded to fragment X.171 In contrast to 
the levels of XLFDP's, the levels of plasma BBI-42 levels were significantly elevated 
(p<O.OI) in the group receiving 150 mg t-PA as compared to values in the group given 
100 mg. This indicates a more intense fibrinogenolysis following administration of the 
higher dose. It might be concluded that increasing the dose of t-PA from !00 mg to 
ISO mg results in an enhanced fibrinogenolysis, but has no influence on the extent of 
secondary fibrinolysis. This finding was confirmed in another study 66 following n-PA 
infusion in normal healthy volunteers. and may be used to define dose regimen since 
it was demonstrated that a state of strong fibrinogenolysis is associated with bleeding 
complications. 167 The study 66 demonstrates, that an increase of fibrin degradation 
products. as assessed by the EIA for FbDP, after administration of n-PA is no evidence 
for lysis of the thrombus, but merely for lysis of a body-pool of fibrin. 
Systemic effects of thrombolytic therapy were also assessed by measuring plasma D-
dimer levels by EIA. D-dimer levels were in the upper limit of the normal range (0.4 
ug/ml) at the time of diagnosis for AMI before treatment and increased significantly 
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(p<O.OOI) 10 2.7ug/ml during rt-PA infusion. 172 However. elevated of plasma D-dimer 
(of 980 ng/ml) were also observed in normal volunteers after t-PA infusion 173, 
suggesting that another fibrin pool is lysed in addition 10 the coronary thrombus (e.g. 
circulating soluble cross-linked fibrin polymers). As a consequence, an increase of D-
dimer levels following t-PA administration is no evidence for lysis of the thrombus. 
This view is supported by the observation that there is a discrepancy between 
thrombolysis (i.e. reperfusion) and the elevation of plasma D-dimer levels."' 
XLFDP levels were measured by EIA in patients with AMI presenting with and without 
complications. 175 The complications were ventricular tachycardia or fibrillation requiring 
electrical countershock. mural thrombus detected by echocardiography, severe 
congestive heart failure defined as Class IV by M!RU criteria or death within 72 hours. 
The used cut-off value for test positivity was 300 ng/ml. The sensitivity and specificity 
of the EIA for the detection of complications in patients presenting early after onset of 
symptoms (<8 hours) were 80% and 81% respectively. The prevalence of the 
complications was 17% and the positive and negative predictive values were 47% and 
95% respectively. In patients presenting late after (>8 hours) onset of symptoms the 
sensitivity, specificity. positive and negative predictive values were 63%, 67%, 56% 
and 73% respectively, at a prevalence of 40%. It can be concluded that normal levels 
of XLFDP alone in patiems with AMI can not exclude the presence of complications. 
No correlation was obser;ed between the size of the infarction and the levels of 
XLFDP. The normal levels of XLFDP found in patients with uncomplicated AMI's 
after early onset of symptoms, may be indicative for impaired fibrinolysis, as has been 
suggested before.'"·m It was demonstrated that the plasma levels of XLFDP's in man 
20 days (mean) after discharge from hospital following a myocardial infarction (MI) 
were higher (p<O.OOJ) than the XLFDP levels in the age matched controls selected 
from a general practice list, suggesting an increased thrombogenesis. fibrinolysis or 
both in persons who suffered from Ml. 179 
Using an EIA for FbDP. it was shown that patients with unstable angina had elevated 
plasma levels of FbDP (]YO.OOI) when compared to norrnal controls or patients with 
acute AMI.'" The FbDP le·;els in patients with stable angina was only slightly elevated 
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when compared to control levels (0.01 <p<0,02), but no difference was observed with 
the levels in patients with uncomplicated AMI (p<O.OO!). The level of FbDP's 
remained high in patients with recurrent episodes of chest pain, but declined in patients 
who had only one episode of chest pain. It was suggested that significantly increased 
FbDP levels in patients with unstable angina may be indicative for an ongoing 
thrombolytic process, while the absence of elevated FbDP levels in patients with AMI 
may suggest that clot dissolution is not taking place. However, this could not be 
confirmed in another study by measuring plasma D-dimer levels by EIA. 181 
Both patients with AMI and patients with unstable angina had moderate elevations of 
plasma D-dimer as compared to patients with stable angina181 The sum of the FbDP 
and FgDP levels. as measured by EIA, correlated (r=0.98) with the level of TDP in 
patients with AMI following rt-PA treatment."' Normal values for FgDP and TDP in 
plasma are below 0.25 ug!ml.''-''·' 82 A" rise of FgDP and TDP was observed in patients 
with AMI two hours after infusion of SK.''-'6·182 The amount of FgDP was slightly less 
than the amount of TDP. suggesting that nearly all circulating degradation products 
were derived from fibrinogen."·''' The clearance of FgDP paralleled that of TDP and 
a half-life time in the circulation of 5 hours was found. 182 
T-PA infusion in patients with AMI resulted in elevated levels of FbDP, as detected by 
EIA (mean: 2.7 ug/ml).'" As mentioned, increased levels of FbDP were also found in 
normal healthy volunteers following rr-PA infusion (mean:0.8 ug/m\).66 In that study, 
no significant differences in FbDP levels were found between volunteers who received 
a rt-PA dose of 0.25mg/kg or 50mg/kg, suggesting that the extent of lysis is 
comparable in the two groups. It was concluded that an increase of FbDP' s is not a 
specific marker of intracoronary lysis. but also reflects systemic lysis of fibrin. This 
view is supported by another study."" 
In summary, application of the EIA for XLFDP's demonstrated that the lysis of fibrin 
induced by administration of t-PA persists longer than by SK. The occurrence of 
fibrinogenolysis. as assessed by an EIA for FgDP. has been demonstrated during rt-PA 
and SK therapy and possibly contributes to an increased bleeding risk.167 Detection of 
cross-linked degradation products by EIA can not be used to predict recanalization in 
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patients with AMI and the levels of XLFDP do not correlate to the size of an 
infarction. Elevated plasma levels of fibrin degradation products are not specific 
markers for the extent of fibrinolysis induced by thrombolytic therapy. The increase of 
FbDP levels during thrombolytic therapy is probably caused by lysis of an other body 
pool of fibrin outside the thrombus. Further studies are needed to determine the origin 
of the fibrin pool that is lysed in addition to the coronary thrombus. 
Malignancies 
It has been shown that the coagulation system is activated in case of leukemia or solid 
malignant tumors. 147' 185· 1$ 
Tumor associated fibrinolysis is supposed to play a role in the local invasion or 
metastatic dissemination of certain malignancies. Some studies demonstrated increased 
levels of plasminogen actintors in the blood of patients with carcinomas which may 
contribute to an enhanced fibrinolysis.' 85·19o.192 However. others reported a reduced 
fibrinolytic activity in cancer patients. 193·194 
The new assays were applied to measure the level of fibrin( ogen) degradation products 
in patients with various malignant tumors. 
With EIA"s for FgDP and D-dimer it was shown that patients with malignancies had 
significantly higher plasma levels of FgDP (p<O.O!) and D-dimer (p < 0.05) as 
compared to the levels in age-sex matched healthy controls. 185 This suggests that 
fibrinolysis is accompanied by fibrinogenolysis in patients with malignancies. 
In tissue specimen of patients with ovarian cancer (Figo stage Ill and IV) or breast 
cancer (T,-TJN0-N2) elevated levels of D-dimer. as assessed by EIA. were found 
relative to D-dimer levels' in tissue specimen of benign controls.195 It was shown that 
the D-dimer levels in ovarium cancer tissue were higher than in tissue of patients with 
breast cancer. This was confirmed in another study.196 
Using an EIA for D-Dimer measurements in plasma it was shown that patients with 
ovarian cancer or cervical carcinoma had significantly (p < 0.01) elevated levels of 
plasma D-dimer when compared to D-dimer levels in norrnal healthy controls.'" 
These findings suggest that fibrinolysis is a common feature in patients with 
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malignancies. With an ElA for the assessment of TOP's. it was shown that 74% of 
patients with ovarium cancer treated by chemotherapy had increased levels of TDP' s 
as compared to normal values (<110 ng/ml). 19 In a majority of these patients (no 
percentage is mentioned) a decrease of the tumor mass (serially assessed by 
laparoscopy, CT scanning 0r second look operations) was accompanied by a decline in 
plasma TDP levels. Since it is possible to detect low levels of TDP (i.e. patients in 
partial remission) with this EIA, it may be particularly valuable in combination with 
the tumor marker CA 125. The latter has been shown to lack sensitivity in detecting 
small tumor masses, which are observed by second look operations.198 More studies are 
needed to confirm these findings. 
By E!A's, elevated plasma levels of fibrin(ogen) degradation products were also found 
in patients with carcinoma of the liver (FbDP,FgDP and TOP 122), lung cancer (0-
Dimer 200) and acute promyelocytic or myeloid leukemia (D-Dimer 87•199; XDP 157• 
FbDP, FgDP, TDP and X-oligomer 199). 
The studies mentioned above. using the new plasma assays, demonstrate that the levels 
of fibrin(ogen) degradation products are elevated in patients with malignancies, which 
may indicate that the fibrinolytic system remains active in these patients. 
Conclusions 
In this paper we discussed the possible clinical utility of assays for determination of 
degradation products of fibrin and fibrinogen. We pointed out that assays based on 
polyclonal antibodies and performed in serum are unreliable and therefore their clinical 
use is limited. Until recently it was not possible to determine the extent of primary 
activation of the fibrinolytic system specifically. The new assays are performed on 
plasma and make it possible to quantify the extent of fibrin(ogen)olysis reliably. 
Furthermore they allow discrimination between the degradation products of fibrin and 
of fibrinogen, since a specific assay has been developed for separate and specific 
determination of fibrinogen degradation products. 
Fibrinolysis appears to be associated with (low grades of) fibrinogenolysis. The process 
of secondary fibrinolysis, as derived from FbDP and D-dimer levels, appears to 
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predominate in deep venous thrombosis, pulmonary embolism, sickle cell disease, 
myocardial infarction and unstable angina. It was shown that thrombolytic therapy 
results in a pronounced fibrinogenolysis (primary fibrinolysis), as assessed by the levels 
of FgDP. The occurrence of an extensive fibrinogenolysis was also observed during 
orthotopic liver transplantation. Several diseases, such as DIC, malignancies, liver 
disease and renal diseases, exhibit both fibrinogenolysis and fibrinolysis secondary to 
an activated state of coagulation. 
The EIA for plasma D-dimer can be used to exclude the diagnosis in patients clinically 
suspected for DVT and ascending venography is not required. The semiquantitative 
latex assays for D-dimer can not be used for this purpose. Plasma FbDP levels, as 
detected by EIA, reflect decrease in thrombus size and may be used to monitor efficacy 
of heparin treatment. Low initial values of FbDP are predictive of poor thrombus 
dissolution in patients with DVT following SK or UK therapy. Elevated plasma levels 
of cross-linked fibrin degradation products have been measured during thrombolytic 
therapy of AMI. They are derived mainly from extracoronary sites and are non-
predictive of recanalization following thrombolytic therapy. 
Plasma Fibrin degradation products levels are related to severity of liver cirrhosis and 
renal disease, but can not be used as markers of renal function. The high sensitivity of 
the EIA 's made it possible to detect increased levels of fibrin degradation products 
during steady state in patients with sickle cell disease. The observed increased 
fibrin(ogen) levels during normal and complicated pregnancy suggest that fibrinolysis 
is not necessarily depressed. The fibrinolytic system remains active in patients with 
malignancies. as demonstrated by elevated levels of D-dimers and FbDP's. 
The fo!lowing guidelines for future studies are suggested. As mentioned in the 
introduction, a disturbance in the haemostatic balance will presumably be reflected in 
the products of both coagulation and fibrinolysis. In this article we focussed on 
fibrin(ogen)olysis only. Detection of fibrin(ogen) derivatives by the monoclonal 
antibody based assays provides valuable information on haemostasis in several diseases. 
However, it is conceivable that more information can be obtained when the products 
of the two opposing processes coagulation and fibrinolysis are simultaneously 
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measured. This possibility is available. Soluble fibrin, the product of an activated 
coagulation system, can also be assessed by EIA in plasma2 " 25 In the future, studies 
may be performed using a combination of an EIA for a coagulation product (i.e. soluble 
fibrin) and an EIA for a fibrinolysis product (i.e. FbDP or D-dimer). 
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ABSTRACT 
New plasma assays for fibrin( ogen) degradation products have become available which 
are based upon monoclonal antibodies and can be performed in plasma. In this smdy 
we have evaluated four of such specific enzyme immuno assays i.e.: for the total of 
degradation products of fibrin and of fibrinogen (TDP), fibrin degradation products (D-
dimer and FbDP) and fibrinogen degradation products (FgDP) in patients suspected of 
having deep venous thrombosis of the leg (DVT) and patients with cirrhosis of the 
liver. In each of the (sub)groups of patients, a very good correlation (0.90< r <0.98) 
was observed between the actually measured TDP values and the calculated sum of the 
separately measured FbDP and FgDP levels. Only 2% (5 patients) of the cases showed 
a discrepancy of more than a factor two between the found TDP values and the 
calculated sum of the measured FbDP and FgDP levels. 
About 90% of the fibrin degradation products were crosslinked. FbDP levels correlated 
well with the FgDP levels (0.72< r <0.94) and D-dimer levels (0.82< r <0.91) in both 
patients with DVT and cirrhotics. In those patients also a good correlation (0.67< r 
<0.83) was observed between FgDP and D-dimer levels, but not in patients suspected 
of having DVT but with a normal lPG test result. Secondary fibrinolysis appeared to 
be accompanied by fibrinogenolysis. 
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INTRODUCTION 
For at least two decades, the measurement of the products of plasmin digestion of fibrin 
and fibrinogen has been •Jsed to assess the extent of fibrino(geno )lysis in several 
clinical conditions (I-ll). The levels of FDP's were mostly measured in serum using 
a variety of procedures (13). The Thrombo-Wellco test and the tanned red-cell 
hemagglutination inhibition assay are well known examples of such serum-based assays 
(13). These assays have been evaluated in order to determine their potential both in the 
diagnosis and in the monitoring of the effect of treatment of different diseases (1-7). 
Since most of these classical assays for FDP assessment are based upon polyclonal 
antibodies which cross-react with fibrinogen, their use is limited to serum samples. 
Serum~ however, is known to be a notorious source of artifacts and it has been 
demonstrated that, in many cases, the currently used assays for FDP assessment in 
serum do not reflect the true level of FDP in plasma (14). Falsely positive results can 
be expected if residual fibrin or fibrinogen in serum reacts with the antiserum used to 
detect FDP (14) or if lysis occurs during serum preparation. Too low or falsely negative 
results may be obtained during serum preparation if certain degradation products, e.g. 
fragment X, coagulate (15) or become adsorbed to the clot (14,!6). As a consequence, 
data based on these serum assays should be interpreted with caution. 
Since a few years, new assays have become available for the quantitative determination 
of fibrin(ogen) degradation products. These enzyme immunoassays (EIA's) are based 
upon specific monoclonal antibodies each of which is directed against specific epitopes 
of a certain fibrin derivative. They can be performed on plasma samples. thus avoiding 
the serum artifacts. The clinical utility of these assays in several states of diseases has 
been reviewed (21). 
The currently available EIA' s allow the specific determination of degradation products 
of fibrinogen (FgDP) (22), the total of degradation products derived from fibrin and 
fibrinogen (TDP) (23) and fibrin degradation products, FbDP (19) and D-dimer (17, 18, 
28). Using a combination of these assays it is possible to discriminate between lysis of 
fibrinogen and lysis of fibrin (primary and secondary fibrinolysis respectively). It has 
been suggested that secondary fibrinolysis is associated with low levels of 
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fibrinogenolysis (30). 
Theoretically. it may be expected that the calculated sum of the FbDP and the FgDP 
plasma levels will approximate the actually measured TOP values. Such an observation 
has been made in patients with ischemic hean disease and patients with disseminated 
intravascular coagulation (DlC) (29). Secondary or reactive fibrinolysis is reflected by 
thelevels of fibrin degradation products (FbDP), which can be determined by the EIA 
for FbDP (which measures both crosslinked and non-crosslinked degradation products) 
or (when they are crosslinked by factor XIlla) the D-dimer E!A. 
In this study we evaluated these plasma based assays in groups of patients with an 
activated state of coagulation. The aims of our study were: !. To examine whether the 
measured levels of the total of degradation products of fibrin and fibrinogen (TOP) 
correlate with the levels obtained by calculation of the sum of the separately measured 
FbDP and FgDP levels. 2. To compare the levels of fibrin degradation products, 
assessed by the D-dimer E!A. with the levels of fibrin degradation products, as 
determined by the EIA for FbDP. 3. To see whether secondary fibrinolysis is associated 
with fibrinogenolysis by investigating the relationship between FgDP levels and the 
levels of fibrin degradation products, as detected by the EIA's for FbDP and D-dimer. 
PATIENTS AND METHODS 
The following groups of subjects were studied: 
- group 1 consisted of 232 consecutive outpatients clinically suspected of having deep 
venous thrombosis (DVT). which have been described before (24). They were referred 
to the Thrombosis Service Center by their general practitioner. The male: female ratio 
was 63:169. the mean age 67 (range:l7-94) and the mean duration of symptoms 9.5 
days. DVT was assessed by impedance plethysmography (lPG) and the results were 
interpreted according to Hull's criteria (25). The prevalence of DVT in this outpatients 
population was 25% (59 out of 232 patients). 
- group 2 consisted of 31 hospitalized patients with cirrhosis of the liver as confirmed 
by liver biopsy. All patiems were admitted to the hospital for analysis of the severity 
of their liver disease. Based on the Child-Pugh classification (26), the patients were 
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divided in 13 patients with Child A, 9 patients with Child B and 9 patients with Child 
C. The mean age was 49 (range:3!-70) and the male:female ratio was 13:18. 
- group 3: The reference group consisted of 43 apparently healthy hospital employees 
(age range: 22-45). 
In all cases, informed consent was obtained and the research was earned out according 
to the principles of the Declaration of Helsinki. 
Blood samples 
Venous blood samples were collected by venepuncture into vacuum tubes containing 
cold trisodiumcitrate 0. II mol/] (I volume per 9 volumes blood). Plasma was obtained 
by centrifugation for 30 minutes at 2000 x g at 4' C. The plasma samples were stored 
frozen in small aliquots at -70'C until tested and carefully thawed at 37'C prior to the 
start of the assay. 
Assays 
All assays were performed on plasma samples in duplicate. The three used assays for 
the specific determination of the total of degradation products of fibrin and fibrinogen 
(TDP: Fibrinostika TDP). fibrin degradation products (FbDP; Fibrinostika FbDP) and 
fibrinogen degradation products (FgDP; Fibrinostika FgDP) were enzyme 
immunoassays of the sandwich type (Organon Teknika, Tumhout, Belgium). All three 
test kits are based upon the same specific monoclonal antibody as capture antibody 
(FDP-14). FDP-14 has its epitope in theE-domain of the fibrinogen molecule i.e. on 
the BB-chain between amino-acids 54-118. It reacts both with degradation products of 
fibrin and of fibrinogen, but not with the intact parent molecules (27). For the specific 
separate determination of fibrinogen degradation products (FgDP's) in the EIA for 
FgDP, a horse-radish peroxidase (HRP) conjugated monoclonal antibody (Y-18) is used 
as tagging antibody which reacts with fibrinopeptide A-comprising fibrinogen fragments 
(22). The tagging antibody for the specific FbDP assay is a HRP conjugated 
monoclonal antibody (DD-13) against fibrin degradation products (crosslinked and non-
crosslinked) (19). In the TDP assay kit for determination of degradation products of 
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fibrin and fibrinogen, a mixture of the two monoclonals Y-18 (22) and DD-13 (19) is 
used as tagging antibody (27). D-dimer was determined by an enzyme-linked 
immunosorbent assay (Boehringer Mannheim, West-Germany) using a monoclonal anti-
FDP-D.D. antibody as capture antibody, which strongly reacts with a neoantigenic 
determinant in D-dimer and has some cross reactivity with fragment D (28). The 
tagging antibody is a panspecific anti-FDP-D peroxidase-conjugated antibody. 
Statistical analysis 
The difference between the means of the test results in the different groups of patients 
was determined using the Wilcoxon ranksum test (two tailed). Pearson's correlation 
coefficient was calculated to determine the relationship between the plasma levels of 
fibrin(ogen) degradation products by using linear regression analysis. 
RESULTS AND DISCUSSION 
The median and range of the plasma levels (in ug/ml) of TDP, FbDP, FgDP and D-
dimer in the different groups of subjects are shown in table I. 
Table I. 
group I group 2 group 3 
(n=232) (n=31) (n=43) 
FbDP 0.55 0.61 0.19 
(0.17-14.6) (0.21-8.2) (0.17-0.45) 
FgDP 0.36 0.34 0.19 
(0.17-9.6) (0.23-1.27) (0.17-0.29) 
IDP 0.88 0.97 0.42 
(0.21-23.1) (0.29-!0.3) (0.2!-0.65) 
D-dimer 0.66 1.1 0.14 
(0.08-13.7) (0.12-8.0) (0.05-0.33) 
The median a.~d range of the plasma concentrations (in ug/ml) of FbDP, FgDP, 
TDP and D-dimer in patients suspected for DVT (group !),patients with 
cirrhosis of the liver (group 2) and norrnal healthy controls (group 3). 
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In both groups of patients, those suspected of having DVT and in the group of patients 
with cirrhosis of the liver, the plasma levels of FbDP, FgDP, TDP and D-dimer were 
higher than the corresponding plasma levels in normal healthy controls (in all cases 
P<O.OOO!). Among the group of patients suspected of having DVT, those with 
confirmed DVT had elevated plasma levels (p<O.OOO!) of fibrin(ogen) degradation 
products when compared to the levels in patients with a normal lPG test result. 
In this study we have evaluated the correlation between the plasma levels of 
fibrin(ogen) derivatives, as determined by EIA's for FbDP, D-dimer, FgDP and TDP 
in patients suspected of having DVT and cirrhotic patients. The correlation coefficients 
of the fibrin(ogen) degradation products are shown in table 2. 
suspected DVT con!rrmed DVT noDVT cirrhosis normals 
(n=232) (n=59) (n=l73) (n=31) (n=43) 
TDP versus FgDP + FbDP 0.94 0.92 0.90 0.98 0.401) 
FbDP versus D-dimer 0.81 0.82 0.35 0.91 0.35" 
FgDP versus FbDP 0.93 0.94 0.45 0.72 0.65 
FgDP versus D-dimer 0.81 0.83 O.QI~ 0.67 0.39" 
All P values were< 0.0001, except: 1) p < 0.05; 2) p ::::: ns 
Table 2. Correlation coefficients of fibrin(ogen) degradation products levels in different 
(sub)groups of patients. 
In the patients suspected of having DYT (fig 1) and patients with cirrhosis of the liver 
(fig 2). the actually measured plasma levels of the total of fibrin and fibrinogen 
degradation products (EIA for TDP) showed a very good correlation (0.90< r <0.98, 
p<O.OOO!) with the values calculated by adding the measured levels of FbDP to the 
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levels of FgDP. This obs~rvation is in accordance with observations by others in 
patients with ischemic heart disease and DIC (29). The correlation between TDP and 
the sum of FbDP and FgDP did not differ much in the subgroup of patients with 
confirmed DVT (r=0.92) and patients with a normal lPG test result (r=0.90). The 
correlation between the measured TDP values and the calculated sum of the measured 
FbDP and FgDP levels in the whole group of patients suspected of having DVT is 
shown in figure I. 
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Fig 1. Correlation between t!1e measured TDP values and the calculated sum of the FbDP and 
the FgDP levels (in ug!ml) in patients clinically suspected of having DVT (n=232). 
In five of the 232 patients suspected of having DVT, we found a discrepancy of more 
than a factor two between the measured TDP levels and the calculated sum of the 
FbDP and FgDP levels . The ratio (FbDP+FgDP)(fDP was higher than 2 in four 
subjects who happened to have an lPG examination with a normal test result. In one 
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patient with an abnormal lPG test result, the ratio was only 0.13. In this latter case, it 
means that the plasma levels of fibrin(ogen) degradation products obtained by the EIA 
for TDP was 7.88 times higher than the values obtained by calculating the sum of the 
FbDP and the FgDP levels. The reason for this is not clear. None of the patients with 
cirrhosis of the liver nor the healthy controls had (FgDP+FbDP)ffDP ratios above 2.0 
or below 0.5. 
T ·=D~P~(=ug~/~m~l)~-------------------------------------, 100 <= 
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Calculated sum of FbDP + FgDP (ug/ml) 
Fig 2. Correlation between the measured TDP values and the calculated sum of the FbDP and 
the FgDP levels (in ug/ml) in patients with cirrhosis of the liver (n=31). 
Secondly, we investigated the correlation between the plasma levels of fibrin 
degradation products as measured by the D-dimer EIA and the ElA for FbDP. A good 
correlation was observed between D-dimer values and FbDP values (both of which 
reflect secondary fibrinolysis) in patients with confirmed DVT and patients with 
cirrhosis of the liver (0.82< r <0.92, p<O.OOOI). 
The correlation coefficient for the FbDP and D-dimer values was r = 0.81 (p<O.OOOl) 
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in all patients suspected of having DVT (see figure 3). This correlation was the about 
same in the subgroup of pctients with confirmed DVT (r=0.82; p<O.OOOl) and poor in 
the subpopulation of patients with a negative lPG test result (r=0.35; p<O.OOOI). 
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Fig 3. Correlation between plasma levels of FbDP and D-dimer (in ug/ml) in patients 
suspected of having DVT. 
The correlation between FbDP and D-dimer in patients with cirrhosis of the liver is 
shown in figure 4. 
In contrast to the EIA for D-dimer. which only detects crosslinked fibrin degradation 
products, the FbDP EIA measures both crosslinked and non-crosslinked fibrin 
derivatives. When one assumes that the calibration materials in the FbDP and the D-
dimer EIA are comparable. one can conclude from the equations of the regression lines 
in figure 3 and 4, that about 90% of the measured FbDP levels consisted of D-dimer. 
This suggests that nearly all of the measured fibrin degradation products are crosslinked 
in those patients. We are aware of only one study that has described a correlation 
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(r=0.72, p<O.Ol) between D-dimer values and FbDP levels (30). However, this 
concerned a different 
D-dimer EIA using another monoclonal antibody (DD-386/22). 
The third purpose of our study was to examine whether secondary fibrinolysis is 
accompanied by fibrinogenolysis. In each of the (sub)groups of patients, the FgDP 
levels correlated less with D-dimer values than with FbDP levels (table 2). The 
observation of positive correlations between plasma levels of fibrin degradation 
products, as assessed by EtA's for FbDP and D-dimer, and the FgDP values confmns 
earlier observations that secondary fibrinolysis seems to be accompanied by lysis of 
fibrinogen (30). Interestingly, both the correlations between FgDP and FbDP and 
between FgDP and D-dimer levels were higher in the reference group (r=0.65, r=0.39 
respectively) than in the group of patients with a negative lPG test (r=0.45, r=O.Ol 
respectively). We have no explanation for the lack of correlation (r=O.Ol, p=ns) 
between D-dimer and FgDP levels in patients with a negative result of IPG 
examination. This observation, however, does not necessarily imply that there is no 
relationship, but rather that there is no linear relationship. 
In general. the correlations between the fibrin(ogen) degradation products were lower 
in normals than in the different (sub)groups of patients. This may be explained by the 
fact that the fibrin(ogen) concentrations in normals are generally very low. Following 
the manufacturers instructions for dilutions of the samples, this means that the 
concentrations have to be read from the lower (nearly horizontal) part of the sigmoidal 
shaped calibration curves, and this yields inaccurate results. When this study was 
finished, we learned that lower dilution factors than 20-fold (as prescribed by the 
manufacturer) are allowed. This might improve the correlations. Summarizing, we 
found that: 1. The levels of the total degradation products (TDP EIA) show a very good 
correlation with the calculated sum of the measured FbDP and the FgDP levels. 2. 
There is a good correlatio~ between plasma D-dimer and FbDP levels and most of the 
fibrin degradation products were crosslinked. 3. Secondary fibrinolysis appeared to be 
associated with fibrinogenolysis. 
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Fig 4. Correlation between FbDP and D-dimer plasma levels (ug/rnl) in patients with cirrhosis 
of the liver (n=31). 
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ABSTRACT 
We have studied the diagnostic value for deep venous thrombosis (DVT) of an enzyme 
immunoassay (ElA) for the detection of D-dimer in plasma of 239 consecutive out-
patients suspected of having DVT by their general practitioner. DVT was conf"mned by 
impedance plethysmography in 60 patients. Using the 95"' percentile range of 42 
healthy volunteers, the sensitivity for the detection of DVT was 92%, with a specificity 
of 21%. In our population with a prevalence of 25%, the D-dimer E!A showed a 
negative predictive value of 88% and a positive predictive value of 28%. We conclude 
that this D-dimer ELISA has limited value, either to confmn or to exclude DVT in out-
patients. 
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INTRODUCTION 
The diagnosis of deep venous thrombosis (DVT) based upon clinical signs and 
symptoms only, is confirmed by objective testing in less than 50% of the cases [l-3]. 
In order to avoid unnecessary exposure to the risk of haemorrhagic complications due 
to anticoagulant treatment [4], the need for confirmative diagnosis by objective methods 
is widely accepted. The gold standard for the diagnosis of DVT, contrast venography 
[5], is an invasive, often painful and expensive technique that requires special expertise 
[6]. Therefore several non-invasive alternatives have been developed, of which 
impedance plethysmography (lPG) [7-10], ultrasonography [II, 12] and 1251-fibrinogen 
leg scanning [13] have extensively been evaluated. lPG has shown to be a practical 
non-invasive alternative for the diagnosis of proximal DVT of the leg in outpatients [8-
!0]. 
In the past, laboratory assays have also been investigated to establish their potential role 
in the diagnosis of DVT [14-20]. Most of these assays were based upon the idea that 
the presence of products in the circulation, resulting from plasmin mediated lysis of 
fibrin(ogen), might be a useful marker of a thrombotic event. Because these assays 
employed polyclonal antibodies which crossreact with fibrinogen, their use is limited 
to serum samples. It has been demonstrated, however, that results obtained by these 
serum-based assays are unreliable [21]. Other laboratory assays focused upon the 
assessment of substances generated during thrombus formation, such as fibrinopeptide 
A and B-thromboglobuline. but with disappointing results [22-24]. 
Assays have now become available for the detection of fibrin(ogen) degradation 
products in plasma [25-30]. They can be divided in (semi-quantitative) latex 
agglutination assays and (quantitative) enzyme immunoassays (E!A). These assays are 
based upon monoclonal antibodies with a well defined specificity directed against 
epitopes of a certain fibrin(ogen) derivative and can be performed in plasma samples. 
The D-dimer EIA is a well known representative of these plasma assays. Plasmin 
induced lysis of cross-linked fibrin produces derivatives containing D-dimer fragments, 
i.e. two covalent! y bound D-domains [31] and fragment E. Therefore the presence in 
blood of circulating fibrin derivatives containing D-dimer are specific markers of a 
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thrombotic process and its >ubsequent reactive fibrinolysis in vivo. The purpose of this 
study was to determine the rest characteristics of the D-dimer EIA for the diagnosis of 
deep venous thrombosis in outpatients. 
PATIENTS AND METHODS 
The study comprised consecutive outpatients clinically suspected of having DVT who 
were routinely referred to the Thrombosis Service Center Rotterdam by their general 
practitioner. The same group of patients has been used to determine the test 
characteristics of the assays for Thrombin-antithrombin Ill (TAT) complexes. 
crosslinked and non-crosslinked fibrin degradation products (EIA for FbDP). fibrinogen 
degradation products (E!A for FgDP) and the total degradation products of fibrin and 
fibrinogen (EIA for TDP) [32]. Informed consent was obtained from each patient before 
lPG was performed and a venous blood sample was drawn. Blood samples were coded 
and handled independently from the lPG result. All lPG results were interpreted by one 
of the authors according to the criteria described by Hull [33]. 
The study was carried out according to the principles of the Declaration of Helsinki. 
Venous blood samples were obtained from the antecubital vein into vacuum tubes con-
taining nisodiumcitrate 0.11 mol/! (9:1). Within 2 hours after collection. blood was 
centrifuged at 1500 x g for 10 minutes at IO'C. Plasma was then collected and stored 
frozen in small aliquots at -70°C. and carefully thawed prior to the assay. Venous blood 
samples of forty-two oste.Jsibly healthy hospital employees (age 22-35 years) were 
handled identically and tested for normal reference values. 
D-dimer was determined in plasma (in duplicate) by a sandwich type EJA (Boehringer 
Mannheim. Mannheim. Germany). using a specific monoclonal antibody (anti-FDP-
D .D.) as capture antibody. which strongly reacts with a neoantigenic determinant in D-
dimer and to a lesser extent with fragment D [34]. The tagging antibody was a 
panspecific anti-FDP-D peroxidase conjugated antibody. 
Statistical analvsis 
Differences in results of ptient groups have been tested by means of the Wilcoxon 
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Rank Sum test (two tailed). Any probability less than 0.05 was considered to represent 
a significant difference between the studied samples. 
RESULTS 
A total of239 consecutive outpatients were entered into the study. DVTwas confirmed 
by lPG in 60 patients; in 10 of these patients the lPG convened to abnormal in the 
second examination. one week after the first examination. Seven patients were excluded 
because of improper handling of the plasma samples. The basic characteristics of the 
total of 232 patients that remained for analysis are shown in table I. Of these, 59 
patients (25%) had an abnormal lPG examination of whom 27% (!6 subjects) had a 
prior history of DYT. The median delay between onset of symptoms and the first lPG 
examination was 8 days in lPG positive patients and 10 days in patients with a normal 
lPG test result. This difference was statistically not significant (p=0.24). No relationship 
was found between D-dimer levels and duration of symptoms in lPG negative patients 
(p=0.03, p=0.67) or lPG postive patients (p=O.l6. p=0.23). 
Within patients that were clinically suspected for DVT, the median D-dimer plasma 
levels in patients with a normal lPG examination was 528 (range; 10-5172) ng/ml, while 
those with a abnormal lPG examination had a median D-dimer level of 1236 (range:6-
16000) ng/ml. The median D-dimer plasma levels in 42 healthy volunteers (the 
reference group) were 148 (range: 53-330) ng/ml (Table II). The cut off point for test 
positivity (268 ng/ml) of the D-dimer EIA was obtained by using the 95~ percentile of 
the measured D-dimer plasma levels of the normal reference group. 
Mean plasma D-dimer values were higher (p<O.OOOJ) in patients with DVT. as 
confirmed by an abnormal lPG. when compared with the values in symptomatic non-
DVT patients. as determined by a normal lPG examination. Funhermore. symptomatic 
non-DYT patients had elevated (p<O.OOOJ) D-dimer levels in comparison to the 
reference group. 
As can be seen in table Ill. 92% of the patients with DVT had D-dimer levels above 
the cut off point for test positivity, leaving 5 cases with a false negative result. Among 
the 173 patients. in who DVT could not be confirmed. there were 137 cases 
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Table I. Characteristics of consecutive outpatients with suspected deep venous thrombosis. 
N 
Male/Female 
Age* 
Prior history of DVT 
Duration of syrnptoms*(in days) 
* Median and range 
IPG abnormal 
59 
23136 
74 (23-94) 
6 (27%) 
8 (1-122) 
IPG normal 
173 
401133 
64 (17-89) 
34 (20%) 
10 (1-700) 
Table II. Test results. of plasma samples of consecutive outpatients with suspected DVT and of 
the reference group. 
Tests Abnormal IPG Normal IPG Reference group 
1236 (6-16000) 528 (10-5172) 148 (53-330) 
* median and range in ng/ml 
Table Ill. Dichotome table showing the results of D-dimer Elisa versus results of IPG 
examination in consecutive outpatients with suspected DVT 
lPG 
Abnormal Normal 
D-dirner~268 nglml 54 137 191 *PV +:54/ 191=28% 
D~dimer<268 nglml 5 36 41 *PV -: 36/ 41=88% 
59 173 232 
Sensitivity Specificity 
54/59=92% 361173=21% 
* PV +: predictive value of a positive test 
PV-: predictive value of a negative test 
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with a false positive result. Therefore the sensitivity and specificity of the D-dimer EIA 
were 92% and 21% respectively. The prevalence of DVT was 25% and the predictive 
value of a positive and negative test result were 28% and 88% respectively. 
DISCUSSION 
The introduction of assays based on monoclonal antibodies, for the detection of 
intermediate or endproducts of fibrinolysis in plasma, has raised new interest to 
investigate the value of laboratory assays in the diagnosis of several diseases involving 
the haemostatic system. 
In this study we have measured the test performance of the D-dimer EIA in outpatients 
who were clinically suspected of having DVT. The D-dimer assay had a sensitivity of 
92%: five of all patients with DVT. confirmed by lPG, had D-dimer levels below the 
cut-off point for test positivity (false negative rate of 8%). The specificity was low 
(21 %). The test characteristics (sensitivity and specificity) are considered to be 
independent of the prevalence of disease (or pretest probability). However, for 
application of the D-dimer assay in daily clinical practice, it is relevant to know 
whether a test result can predict the presence or absence of disease. Therefore it is 
imponant to be aware of the positive or negative predictive value (or post test 
probability) of a given test result. 
In our population, the prevalence of DVT was 25%. A positive D-dimer test was 
followed by an abnormal lPG test in only 28% of the cases (i.e. the positive predictive 
value is 28% ). As a consequence, the observation of elevated D-dimer levels alone in 
patients suspected of having DVT is not sufficient to indicate anticoagulant treatment. 
The predictive value of a negative test result was 88%. Based on a D-dimer test result 
only, the diagnosis DVT will be missed in 12% of the cases with D-dimer levels below 
the cut-off point for test positivity. This is an unacceptably high percentage. 
The sensitivity of the D-dimer EIA in our study is comparable with results reponed by 
others using ascending venography [35-38], but the specificity is lower. This Iauer may 
be explained by the fact that we used lPG to confirm DVT, which has a limited ability 
to detect calf vein thrombosis. The use of ascending venography may lead to a shift of 
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lPG negative patients with elevated D-dimer levels due to calf vein thrombosis to a 
DVT positive classification. which results in a higher specificity. It has been 
demonstrated. however. that safe management with the use of lPG is possible in 
symptomatic outpatients [9]. 
Application of a different cut-off point for test positivity may also influence the test 
results. ln our study it was not possible to reach a l 00% negative predictive value by 
variation of the cut-off point. Furthermore, a difference of prevalence of DVT may alter 
the predictive value of a test result: e.g. when the prevalence decreases, the positive 
predictive value will also fall, but the negative predictive value may rise. 
Other recently developed laboratory tests. like the assays for thrombin-antithrombin 
(TAT) complexes [32.39] and the assays for cross-linked and non cross-linked fibrin 
degradation products (FbDP EIA), for the total of fibrin and fibrinogen degradation 
products (TOP EIA) and for fibrinogen degradation products (FgDP ElA) have also 
been evaluated in the diagr.osis of DVT [32]. Neither of these assays reached a negative 
predictive value of 100%, although it should be noticed that the test characteristics of 
the EIA 's for FbDP. TDP and FgDP has not yet been determined using ascending 
venography in patients suspected of having DVT. 
Other studies, using a semiquantitative D-dimer latex agglutination assay, demonstrated 
that DVT could not be excluded if only based on D-dimer levels below the cut-off 
point for test positivity [35-37]. Formerly developed assays for determination of 
fibrinopeptide A (FPA) and betathromboglobulin (beta-TG) in plasma have also been 
evaluated in the diagnosis of DVT [22-24] and have shown to be of little value in the 
diagnosis of DVT. 
Summarizing, the results cf this study seem to indicate that the D-dimer E!A can not 
be used in our population vf outpatients clinically suspected of having DVT to select 
patients for further diagnostic procedures (lPG). 
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ABSTRACT 
Gram-negative septic shock is an increasingly common event associated with a high 
mortality. Complicating factors, such as multiple organ failure and adult respiratory 
distress syndrome are due to widespread fibrin depositions, and are considered to 
depend largely upon extreme activation of the coagulation pathway. It has recently been 
suggested, however, that impairment of fibrinolysis may also play a role. In this study 
we foccussed on the fibrinolytic system in 30 patients with septic shock, by measuring 
plasma levels of the total fibrin and fibrinogen degradation products (TDP) and 
fibrinogen degradation products (FgDP). Mean TDP and FgDP levels were elevated in 
patients with septic shock and showed a tendency toward normalization during follow-
up. The mortality rate was 50%. No difference could be detected between plasma TDP 
and FgDP levels in survivors and nonsurvivors of septic shock. This study suggests that 
the fibrinolytic system is activated during septic shock. Further studies are needed to 
determine whether activation of the fibrinolytic system in patients with septic shock 
may improve the prognosi;;. 
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INTRODUCTION 
Gram-negative sepsis is an increasingly common clinical event with a mortality rate 
between 20% and 50%. 12 In patients who develop septic shock. mortality exceeds 40% 
and may even approach 90% in patients with serious underlying disease.' 
Endotoxins, lipopolysaccharide, and especially the lipid-A fraction of the gram-negative 
bacterial cell wall, trigger the pathophysiologic response to gram-negative septicemia! 
They exert numerous biological effects, such as generation of vasoactive peptides.S·' and 
activation of coagulation' and complement pathways.' Endotoxin is also a potent 
stimulator for the release of tumor necrosis factor (TNFa) from macrophages and 
monocytes! TNF activates factor X and thus the common coagulation pathway. 10 
Septicemia is frequently associated with disturbances of the hemostatic balance.11 
During septic shock, decreased levels have been detected of prekallikrein and 
coagulation factors XII, XI and Vll, suggestive for consumption of these factors. 12.1' 
The activation of the coagulation system may cause disseminated intravascular 
coagulation (DIC) with widespread depositions of fibrin in the microvasculature and 
subsequent development of multiple organ failure. 14.I5 The activation of kallikrein in 
turn m<>y also cause the liberation of bradykinin and the activation of plasmin. 
Bertozzi and coworkers recently demonstrated that inhibition of fibrinolytic activity due 
to an increase in urokinase inhibitors and amiplasmins contributes to the formation and 
persistence of hyaline membranes in the lung and thus to the development of adult 
respiratory distress syndrome. a common complication of septic shock.16 Furthermore 
it has been demonstrated that endotoxin administration to normal subjects results in 
early activation of fibrinolysis through release of tissue plasminogen activator (t-PA), 
which is abruptly terminated by a rise of plasminogen activator inhibitor I (PAl-l) 
activity." Extremely high PAl-l levels have indeed been encountered in patients with 
septicaemia12.1 8•19 suggesting that plasmin mediated lysis of fibrin and fibrinogen may 
be impaired during septic 'hock. 
Fibrinolysis is an important mechanism in protecting the circulation from massive 
thrombosis and is reflected by the formation of degradation products of fibrin (FbDP) 
and fibrinogen (FgDP). Until recently, blood levels of fibrin and fibrinogen 
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degradation products could not be detected reliably, because they could only be 
assessed in serum. The use of serum samples leads to unreliable results?021 
During the past few years, enzyme immuno assays (EIA's) have become available for 
quantitative assessment of fibrin and fibrinogen degradation products in plasma. The 
aim of our study was to investigate the fibrinolytic state in patients with septic shock 
by measuring degradation products of fibrinogen (FgDP) and the total of fibrin and 
fibrinogen degradation products (TDP) in plasma. 
PATIENTS AND METHODS 
This investigation was performed as an ancillary study to the so called Swiss-Dutch 
nial, which was designed to determine the efficacy of hyperimmune lgG against E-coli 
J5 in comparison to a normal lgG preparation in patients with gram-negative septic 
shock.22 Blood samples were obtained from 30 consecutive patients in the Netherlands 
(participating centres and principal investigators: Sint Radbout Hospital Nijmegen (E. 
Kalter), University Hospital Utrecht (J. Schellekens and J. Verhoef), who fulfilled the 
inclusion criteria of the Swiss-Dutch trial: L The presence of a gram-negative 
bacteremia, a proven or firmly suspected gram-negative focal infection or a clinical 
condition predisposing to gram-negative infection (e.g. granulocytopenia, septic 
abdominal surgery, esophageal surgery or surgery for ruptured aonic aneurysmal and 
2. the presence of septic shock based on clinical grounds and at least one of the 
following signs: oliguria (<30 ml/h), hypothermia (<36°C), hypoxentia (P02<30 mm 
Hg), respiratory alkalosis (pH >7.5 or Pc02<30 mm Hg), metabolic acidosis (pH <7.3 
or base excess <-10 mmol/1), coagulation abnormalities (plasma thromboplastin level 
of <50% of normal, APIT >40s, or the elevation of fibrin split products in serum) and 
thrombocytopenia (<I 00 OOO/mm3 or a decrease of>50% of a previously normal value). 
All patients received standard therapy for septic shock (fluid resuscitation, vasopressors 
and antibiotic treatment) •nd support of the vital functions if required (Swan-Ganz 
catheterization, artificial ventilation and hemodialysis). In addition, the patients were 
randomized to receive a single intravenous dose of 200 mg/kg (max 12 g) of either a 
standard lgG preparation or a preparation of human lgG (J5) antibody to Escherichia 
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coli during one hour. 
Blood samples were taken prior to infusion (t=O), 2 hours after infusion (t=l ), 24 hours 
after infusion (t=2) and after 10 days (t=3). Plasma was obtained by cenrrifuging a 
mixture of nine volumes of blood and one volume of 0.11 M sodium citrate for 30 
minutes at 2000 x g at 4' C. The plasma samples were stored frozen in small aliquots 
at -20'C until tested and carefully thawed at 37'C prior to assay. In order to be able to 
establish normal reference values, venous blood samples were obtained from 43 non-
patient volunteers (male:female = 24:19: median age: 31 yrs, range: 22-45 yrs) and 
processed in an identical manner. 
Assays 
FgDP and TOP were determined in plasma using specific EIA's of the sandwich type 
based on monoclonal antibodies (Organon Teknika, Turnhout, Belgium). The capture 
antibody was FDP-14, the tagging antibody for detection in the FgDP EIA was FDP 
Y-18.23 A combination ofFDP Y-18 and FDP DD-13 was used as tagging antibody in 
the EIA for TOP assessment.'' 
Statistical analysis 
Results are given as mean ± standard error of the mean (s.e.m.), unless reported 
otherwise. Differences between groups were tested by applying the Wilcoxon ranksum 
test for independent samples. Within group differences were determined by Wilcoxon 
matched-pairs signed rank test. Any P value <0.05 was considered to represent a 
significant difference. All reported significance levels were two-sided. Regression 
analysis was performed by method of least squares and the correlation coefficient was 
calculated. 
RESULTS 
The mortality rates were 50% in either of the treatment groups. We therefore analysed 
all data assuming that treatment difference did not exist. 
Of the 30 patients with a gram-negative septic shock (median age:64, range 21-78, 
male/female ratio: 20:10), 15 died due to septic shock; 8 of whom died within 7 days. 
The median plasma values of the TDP and FgDP in normal healthy controls and 
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patients with septic shock are shown in table l. 
The mean plasma TOP concentration in the baseline plasma sample (t=O) of patients 
with septic shock (6.52 ug/ml ± 1.83) was markedly elevated (p<O.OOOI) as compared 
with that of healthy subjects (0.42 ug/ml ± 0.02). In addition, patients with septic shock 
had significantly higher plasma FgOP levels (2.59 ug/ml ± 0.93) than healthy subjects 
(0.20 ug/ml ± 0.004, p<0.0001). 
Patients TDP FgDP 
normals 0.42 (0.21-0.65) 0.19 (0.17-0.29) 
sepsis 3.01 (0.25-42.9) 0.65 (0.25-19.9) 
survivors 2.61 (0.25-42.9) 0.62 (0.25-19.4) 
nonsurvivors 3.09 (0.25-36.5) 0.81 (0.25-19.9) 
death <7 days 3.09 (0.25-36.5) 0.43 (0.25-19.9) 
death >7 days 2.90 (2.29-14.4) 1.01 (0.25-5.50) 
Table I Median and mnge of TDP and FgDP plasma levels (ug/ml) in patients with 
gram-negative septic shock and normal subjects. 
The differences between survivors and nonsurvivors of septic shock at t=O were not 
significant for mean TOP (6.65 ± 2.89 vs 6.38 ± 2.35 respectively. p=0.53) and mean 
FgDP (2.65 ± 1.37 vs 2.47 ± 1.29 respectively, p=0.72) plasma levels. 
The mean ratio of FgDP!fDP in patients with septic shock (0.39 ± 0.05 ug/ml) in the 
first plasma sample was lower (p<O.Ol) than in healthy subjects (0.52 ± 0.02 ug/ml). 
The difference in mean FgDP(fOP ratios between survivors (0.46 ± 0.08 ug/ml) and 
nonsurvivors (0.34 ± 0.06 ug/ml) was not statistically significant (p=0.12). 
Fig l shows the mean plasma levels of TOP. FgOP and the FgOP!fDP ratio of patients 
with septic shock in the first plasma sample, after 3 hours, after 24 hours and after 10 
days. The variation in mean TOP and FgOP values was not significant (0.32<p<0.86 
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and 0.22 <p<0.76 respectively). The mean FgDP{fDP ratio remained unchanged 
(p=0.03) after 3 hours (0.44 ± 0.06 ug/ml). but declined significantly (p<0.005) to 0.29 
± 0.04 ug/ml after 24 hours. During follow-up. no significant differences were observed 
in mean TDP plasma levels (0.39<p<0.71) and FgDP values (0.35<p<0.72) between 
survivors and nonsurvivors. 
FgDP values correlated extremely well with TDP values in the first plasma sample 
(r=0.97, p<O.OOOI, n=30) and after 3 hours (r=0.96, p<O.OOOI, n=29). However, this 
correlation disappeared after 24 hours (r=0.42, p<0.05, n=24) and after 10 days (r=0.33, 
p=0.18, n= 18). 
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DISCUSSION 
In this study we investigated the fibrinolytic system in patients with septic shock by 
measuring FgDP and TLP plasma levels with new sensitive EIA's. One of the 
99 
pathophysiological hallma:-ks of septic shock are the DlC related events, such as fibrin 
deposition at the microvascular level1 Degradation of fibrin, deposited in the 
microvasculature, by a physiological fibrinolytic response is an important mechanism 
of the organism in the defence against massive thrombosis. 
The fibrinolytic activity depends primarily on the balance between t-PA and PAl-l 
activity. Recent studies suggest that the fibrinolytic system may be impaired in 
septicemia through an increased PAl-l activity.18•19 High PAI-I levels appear to be 
associated with a poor prognosis of septic shock.12-'9 Although measurement of both t-
PA and PAI-l seems thus of importance in the prognosis of septic shock, circulating 
levels of fibrin and fibrinogen degradation products could be a more reliable measure 
of their resultant activity in blood. The most tangible evidence for ongoing fibrinolysis 
in blood is the presence of degradation products of fibrin and fibrinogen. Plasma levels 
of TDP and FgDP were markedly elevated in patients with septic shock as compared 
with healthy subjects. This is in agreement with findings of others who found elevated 
D-dimer levels during septic shock 1225 or increased FgDP and TDP levels in patients 
with septicemia20 and suggests that simultaneous activation of both the coagulation and 
the fibrinolytic system occur in these patients. Moreover, the elevated levels of FgDP 
indicate the occurrence of primary fibrinolysis (fibrinogenolysis), which has been shown 
to accompany fibrinolysis in many cases27 . FgDP's possess anticoagulant properties29' 31 
and their presence in plasma could theoretically helping preventing the formation of 
microthrombi. However, this study suggests that their contribution to the course of 
septic shock is limited as no difference could be detected between mean FgDP levels 
of survivors and nonsurvivors. It could well be that their contribution is of greater 
importance at an earlier stage. 
No difference could be observed between survivors and nonsurvivors in mean TDP and 
FgDP plasma levels in the. first plasma sample. Measurements during the follow-up 
period of the whole group showed that there was a tendency to normalization in plasma 
levels of degradation products (see Fig.!). This tendency was slightly more pronounced 
in survivors than in nonsurvivors. but the difference was not significant. Whether this 
latter is due to a type ll error needs to be determined by studying larger groups. The 
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decline of the FgDP[fDP ratio in the sample after 24 hours may be explained by an 
increase of FbDP plasma levels, since TDP is the sum of FgDP and FbDP.28 
In conclusion, this study shows that TDP and FgDP levels are significantly elevated 
during septic shock, indicating the process of ongoing fibrinolysis. No difference could 
observed between levels of degradation products of survivors and nonsurvivors, which 
suggest that the fibrinolytic activity was comparable in both groups. This study was not 
designed to determine whether the extent of fibrinolytic response is adequate for the 
degradation of fibrin deposits and microvascular thrombi during septic shock. Further 
studies are needed to see whether stimulation of fibrinolytic activity. e.g. by preventing 
the increase of PAI-1 or administration of t-PA. has a beneficial effect on the prognosis 
of septic shock. That this may be the case is suggested by experimental results of t-PA 
therapy on glomerular thrombi in the Shwanzman reaction in rabbits?2 
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PHARMACOKINETICS OF LOW MOLECULAR WEIGHT HEPARIN AND 
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BYPASS GRAFTING 
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ABSTRACT 
Peroperative monitoring h~s demonstrated that administering of heparin on empirical 
basis is associated with a wide variation in patient response and elimination rate. This 
problem may be overcome by intervention on the basis of peroperative monitoring or 
by using heparins with different pharmacokinetic properties. When compared with 
unfractionated heparin (UFH), low molecular weight heparins (LMWH) have a higher 
bioavailability after subcutaneous administration, a linear clearance mechanism with a 
prolonged half life and are at least as effective in preventing postoperative vein 
thrombosis. Theoretically these characteristics ofLMWH could lead to more predictable 
levels of heparin activity. 
In this study we compared the pharmacokinetics of LMWH and UFH after an 
intravenous injection in p2tients undergoing aortic graft surgery. Heparin activity was 
measured before heparin administration and at 5, 20, 35, 50, 65, 80, 95 and l!O 
minutes after administration. The anti-Xa activity in the LMWH group showed less 
variation and was more sustained when compared to the UFH group. Fibrin degradation 
products were moderately correlated with the anti-factor Xa levels of the LMWH 
group, but no correlation was found in the UFH group. The anti-factor Xa activity of 
LMWH was, in contrast to that of UFH. not completely reversible by protamine 
administration. The blood loss was comparable in both groups. In contrast to what was 
expected, the pharmacokinetic profiles of LMWH and UFH showed a similarity after 
intravenous injection in patients undergoing aortobifemoral bypass grafting. Factors that 
could have influenced the pharmacokinetic behaviour of the heparins are discussed. 
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INTRODUCTION 
The use of heparin in the surgical treatment of arteries has first been described in 1940 
and it was shown that heparin had a favourable effect on vascular patency'. Gradually, 
the administration of heparin during reconstructive arterial surgery has become widely 
accepted for the prevention of intravascular peroperative thrombosis. At present, the 
majority of surgeons routinely anticoagulate their patients by giving a fixed dose 
heparin (mostly 4000-8000 IU) intravenously'·'. although some prefer a bodyweight 
dependent dose of heparin i.v-'·10• Previously, we have studied heparin levels during 
abdominal aortic reconstructions4. In accordance with other studies2•10-13, it was 
demonstrated that patients response to heparin showed a large interindividual variability, 
which makes it difficult to maintain predictable or adequate levels of anticoagulation 
for all patients. One way to attack this problem may be the close monitoring of heparin 
levels in each patient. another approach is to study the utility of heparins with different 
pharmacological properties. 
The heterogeneous nature of unfractionated heparin (UFH), like its polydispersity of 
molecular weight and different chemical properties. may contribute to the variable 
response in patients. After intravenous administration. the disappearance curve of UFH 
anticoagulant activity. as r.Jeasured with the APTT or with the anti-Xa assay, follows 
non-linear kinetics and is characterized by a rapid initial disappearance phase followed 
by a convex curve". During aortobifemoral bypass grafting. the duration of the aortic 
clamping rime is such. that the UFH elimination will mainly occur in this rapid 
disappearance phase. 
In the search for improvement of heparin therapy, attempts have been made to develop 
heparin derivatives with modified pharmacological and biological properties. One group 
of heparin derivatives, the low molecular weight heparins (LMWH), have become of 
great clinical interest. Some LMWH preparations have already been approved and 
registered for clinical use. LMWH are derivatives of UFH characterized by a shorter 
oligosaccharide chain leng,h and a prolonged half life time in comparison to the parent 
heparin. LMWH' s exert anticoagulant activity in a different way than UFH. A 
minimum of 18 monosaccharide units is needed for the simultaneous binding of 
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thrombin and antithrombin on a heparin template, while the saccharide size needed for 
interaction with factor Xa is smaller15 • Hence, because of their shorter chain length, 
LMWH's have a diminished anti-factor lla activity, which is reflected by a limited 
ability to prolong clotting time, but are potent enhancers of the inhibition of coagulation 
factor Xa. 
Following subcutaneous administration, the bioavailability of LMWH is high (± 90%) 
in comparison with UFH (± 15%)16, which makes it possible to reach therapeutical 
levels in thrombotic patients without dose adjustments17• Analysis of randomized 
controlled level! trials comparing UFH and LMWH in the prophylaxis of postoperative 
venous thrombosis demonstrated a clinically important difference in efficacy in favour 
of LMWW8 After intravenous administration LMViH's follow a linear elimination 
pattern19.21 Theoretically, the altered pharmacokinetic properties of LMWH's could 
result in more predictable levels of heparin activity during aortic reconstructive surgery. 
The purpose of this study was to compare the pharmacokinetics of intravenously 
administered LMWH and UFH in patients undergoing elective aonobifemoral bypass 
surgery. 
PATIENTS AND METHODS 
patients 
The study included consecutive patients undergoing an elective aonobifemoral bypass 
prosthesis operation. Patients were excluded from the study if they had (previous) 
bleeding disorders, if they had taken anticoagulant or anti platelet therapy during 5 days 
prior to surgery or if they had not given informed consent. All exclusions were 
documented. 
A knitted, gelatin impregnated Dacron graft ( Yascutek', lnchinnan, Renfrewshire, 
Scotland) was used for bypass surgery. Standardized techniques of aortic graft insertion 
were used in all procedures. The proximal anastomosis to the aortic neck was made 
either end-to-end when it concerned aortic aneurysmal or end-to-side in case of 
aonoiliac occlusive disease. The distal pans of the graft were sutured end-to-side to the 
common femoral arteries just proximal of the bifurcations of the superficial and deep 
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femoral arteries. Flushing of the graft just before completion of the anastomoses was 
also part of the procedure. 
Study design 
The study was performed as a randomized study to compare the pharmacokinetics of 
LMWH and UFH administered during elective abdominal aortobifemoral prosthesis 
operations. Included patients were randomly assigned to receive LMWH (dosage: 90 
anti-Xa units/kg) or unfractionated heparin (dosage: 80 anti-Xa units/kg). The operating 
surgeons were kept unaware of the assignment. Heparin was administered as a bolus 
injection intravenously 3 minutes prior to clamping of the aorta. 
Apart of the heparinization, no further attempt was made to alter the surgeon· s existing 
empirical protocol. A solution containing 25 anti-Xa IU UFH per ml normal saline was 
used for flushing. Protamine was administered if and as desired by the operating 
surgeon after completion of the anastomosis and removal of the clamps and before 
abdominal closure. Blood samples were taken after induction of anaesthesia (before 
heparin administration). 5 minutes after heparin administration and each 15 minutes 
thereafter until completion of the anastomosis and removal of the aorta clamp. If 
protamine was administered, a blood sample was taken 5 minutes later. 
The study was approved by the medical ethical committees of the University Hospital 
Rotterdam - Dijkzigt. Rotterdam and the St. Antonius Hospital, Nieuwegein, the 
Netherlands. Informed consent was obtained from each eligible patient before entering 
into the study. The study was carried out according to the declaration of Helsinki. 
Heparins 
- UFH: Thromboliquine' (Organon, Oss, the Netherlands) in prepacked syringes of 5 
ml containing 5.000 IU/ml of the highly purified sodium salt of heparin from animal 
source. 
- LMWH: the used LMWH (Kabi 2165, Fragmin', Kabivitrum AB, Stockholm, 
Sweden) was obtained by partial depolymerization of heparin from porcine intestinal 
mucosa with nitrous acid and isolated by ethanol precipitation. Fragminr has an average 
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MW of 4000-6000 Daltons and about 90% of the material between MW 2000-9000. 
The specific anticoagulant activities are about 160 U/mg in an anti-factor Xa assay 
using the chromogenic substrate S-2222 (Kabivitrum, Stockholm) and about 40 U/mg 
in the APTT and thrombin inhibitions assays. Aqueous solutions of Fragmin' were 
supplied in prepacked syringes containing 10.000 IU in a 1 ml solution. 
Laboratory assays 
- Assays were performed using the FP-910 coagulation system (Labsystems, Helsinki, 
Finland) as described earlier'. 
- Heparin activity was assessed by measuring anti-factor Xa activity using the 
chromogenic substrate S-2222, bovine factor Xa and human AT-Ill concentrate (Coatest 
heparin. Kabi Vitrum, Amsterdam, the Netherlands )22 A standard curve was constructed 
by testing normal citrated plasma samples (obtained from apparently healthy hospital 
employees) containing increasing amounts of heparin at concentraripns ranging from 
0-1 U/ml. 
-Activated partial thromboplastin time (AP1T) was determined with actin (Merz Dade, 
Dijdingen, Switzerland)". 
-Fibrin degradation products (FbDP's) were quantitatively determined in plasma using 
an enzyme immunoassay (E!A) of the sandwich type (Organon Teknika, Turnhout, 
Belgium). This E!A is based upon a monoclonal antibody as capture antibody (FDP-
14). The tagging antibody was a horse-radish peroxidase (HRP) conjugated monoclonal 
antibody (DD-13) against the D-dimer''. 
- Platelet count. hemoglobin and hematocrit were determined in EDTA-blood. 
Thrombotest (TT) was also determined. 
Blood samples 
Venous blood samples were collected from an arterial line into 5 ml tubes containing 
3.2% trisodium citrate (9:1). The first 10 ml of blood was discarded to avoid 
contamination of the sample with heparin used for flushing. The blood samples were 
immediately cooled on melting ice and were centrifuged in an Eppendorl centrifuge 
(3.5 min, 10.000 g) or a Hettich centrifuge (10 min, 3200 gat 4'C). Plasma samples 
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were stored frozen in smdl aliquots at -70°C and carefully thawed at 37°C prior to 
assay. 
Blood loss 
The intraoperative blood loss was accurately collected and recorded through suction and 
gauzes. 
Statistical analysis 
Results are given as mean ± standard deviation unless reported otherwise. Within 
groups differences between the means were tested using Wilcoxon's signed Rank test 
for paired samples. Differences between the two groups were tested with the two 
sample Wilcoxon ranksum test. All tests were two-sided and any probability less than 
5% was considered statist.ically significant. Pearsons correlation test was used for 
comparison of the APTT and the anti-Xa levels and for comparing the FbDP levels 
with the anti-Xa levels. 
RESULTS 
Patients 
Fifty three consecutive patients underwent elective abdominal aortobifemoral bypass 
grafting. Thirteen patients were excluded from the study. one because a history of 
excessive bleeding during previous surgery, eight because they had been taking 
anticoagulant or antiplatelet drugs within 5 days prior to surgery and four because they 
were unwiHing to give inf0rmed consent. 
Forty eligible patients who were willing to give informed consent entered into the 
study. Twenty patients were assigned to receive UFH and twenty to receive LMWH. 
The patients characteristics are shown in table I. 
The indications for operation were aortoiliac occlusive or aneurysmal disease of the 
aorta. Fifteen patients (38%) suffered from aortoiliac occlusive disease (7 of the UFH 
group and 8 of the LMWH group). Twenty-five patients were electively operated upon 
because of an aortic aneurysma (!3 of the UFH and 12 of the LMWH group). The 
aorta was cross-clamped above the renal arteries (suprarenal) in 15% of the cases (4 
patients in the UFH group and 2 in the LMWH group). The preoperative hematologic 
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Bodyweight age male/female 
Group (Kg) (yrs) ratio 
UFH 75.7 ± 16.1 61.2 ± 11.1 17/3 
LMWH 71.6 ± 8.5 64.9 ± 9.7 18/2 
Total 
Table 1 
73.6 ± 12.7 63.0 ± 10.3 35/5 
Characteristics of patients undergoing elective aortobifemoral bypass 
grafting (mean ± std). 
UFH LMWH 
Platelet count 222 ± 67 233 ±57 
(x 109 /l) 
Haemoglobin 8.6 ±1.1 8.9 ± 0.8 
(mmol/1) 
haematocrit 0.40 ± 0.05 0.42 ± 0.04 
Thromborest 74% ± !7% 65% ± 23% 
APTT (sec) 38.3 ± 12.4 34.8 ± 6.06 
Table 2 Preoperative hematologic data of patients receiving UFH or LMWH. 
Group 
UFH 
LMWH 
Total 
Table 3 
Blood loss Operation time Clamping time 
mean s.e.m. mean s.e.m. mean s.e.m. 
242! 296 235 2! 72 !0 
2098 438 207 13 6! 6 
2255 357 22! 12 66 6 
Intraoperative blood loss (ml), duration of operation (min)and clamping time 
of the aorta (min) in aortobifemoral bypass grafting. Results are given as 
mean and standard error of the mean (s.e.m.). 
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data of both groups were comparable (see table 2). The intraoperative blood loss, the 
operation time and the clamping time of the aorta in both groups are shown in table 3. 
The between groups differences of the means were statistically not significant. 
Heparin levels 
The disappearance curves of the two heparins, as assessed by the levels of anti-factor 
Xa activity, are shown in figure I. 
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The ami-factor Xa activity (IU/ml) before (BH) and after heparin 
administration in patients receiving UFH or LMWH (mean ± SD). The arrow 
indicates an increase of UFH concentrations following flushing of the aona 
with UFH preparations. 
No anti-Xa activity was measurable in any of the samples before administration of 
heparin. Five minutes after heparin infusion, the mean heparin level in the UFH group 
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and the LMWH group were 0.88 ± 0.43 anti-Xa U/ml and 1.06 ± 0.23 anti-Xa U/ml 
respectively. This difference was not significant. 
After removal of the clamps and establishment of flow the mean anti-Xa activity in the 
LMWH group (0.30 ± 0.14 U/ml) was significantly higher (p<0.05) when compared 
with the UFH group (0.21 ± 0.27 U/ml). The anti-Xa activity (mean± SD, in U/ml) 
of the samples drawn at 20, 35, 50, 65, 80 and 95 minutes .after heparin administration 
were: 0.67 ± 0.29 and 0.77 ± 0.18: 0.53 ± 0.28 and 0.59 ± 0.18: 0.44 ± 0.27 and 0.49 
± 0.17; 0.38 ± 0.24 and 0.41 ± 0.17 ;0.40 ± 0.29 and 0.31 ± 0.15; 0.24 ± 0.25 and 0.32 
0.09 ± 0.09 for UFH and LMWH respectively. 
The anti-Xa levels (mean ± std) at 110 minutes after heparin administration were 
significantly higher (p<0.05) in the LMWH group (0.25 ± 0.11 U/ml) when compared 
with the corresponding values in the UFH group (0.05 ± 0.09 U/ml). 
APTT measurements 
UFH group 
The intraoperative APTT values in the samples drawn before heparin administration 
were 51.7 ± 18.2 seconds. Five minutes after heparin administration the APTT was 
more than 300 seconds (which was the maximal detectable time in our assay) in 14 
patients. Six patients had APTT levels ranging from 129 to 160 seconds. After 
establishment of flow. 9 p&tients still had APTT levels above 300 seconds. Because the 
maximum measurable AP1T value in our assay was 300 seconds, it was not possible 
to calculate Pearsons correlation coefficients for comparing the APTT values with the 
anti-factor Xa activity. 
LMWH group 
The mean APTT intraoperatively before heparin administration was 51.6 ± 18.4 
seconds. The mean APTT value 5 minutes after heparin administration was 156 ± 76 
seconds. which is significantly lower (p<O.OOl) when compared with the corresponding 
values in the UFH group. None of the patients had APTT levels above the maximal 
detectable level of 300 seconds. After removal of the clamp and establishment of flow 
the APTT was significantly (P<0.05) diminished to 124 ± 46 seconds. No correlation 
H4 
was observed between the APTT levels and the anti-Xa activity (r=0,22; p=ns). 
Fibrin degradation products 
The median FbDP levels of the samples drawn before heparin administration were 
0.630 ug/ml (range: 0.15-2,3 ug/ml) in the UFH group and 0.798 ug/ml (range: 0.15-
13.2 ug/ml) in the LMWH group. As can be seen in figure 2, the mean FbDP levels 
increased significantly during operation in both groups (UFH group: p<O.Ol; LMWH 
group: p<0.05). After completion of the anastomosis and removal of the clamps, the 
median and range (in ug/ml) of the FbDP values were 0.956 (0.10- 3.46) in the UFH 
group and !.53 (0.26 - 28.0) in the LMWH group. The between groups differences of 
the FBDP values were not significant. Pearsons correlation coefficient for the FbDP 
levels and the anti-Xa activity was 033 (p<0.05) in the LMWH group. No correlation 
was found (r=O.Ol4, p=ns) for FbDP levels and anti-Xa activity in the UFH group. 
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Intraoperative FbDP plasma levels {ug/ml) before heparin administration and 
at the end of operation. 
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Reversal of heparin activity 
Protamine chloride was administered in 19 cases (8 receiving UFH and 11 receiving 
LMWH). The dosages varied between 20 and 40 mg. Two patients received protamine 
when heparin activity had already disappeared. No heparin was detectable after 
protamine administration in UFH-patients. Six of the 12 UFH-patients who did not 
receive protamine still had measurable heparin levels (range: 0.1-0.661U/ml) at the end 
of operation. Heparin activity was measurable in 9 of the 11 LMWH-patients who had 
received protamine (range: 0.05-0.42 IU/ml). At the end of operation heparin was 
detectable in all LMWH-patients who had not received protamine (range: 0.05-0.46 
U/ml). 
Intraoperatively. no thrombotic or bleeding complication occurred in any of the patients. 
Postoperatively, two patients of the LMWH group died because of a poor lungfunction 
and asystole respectively. One patient in the UFH group underwent relaparotomy 
because of postoperative blood loss. The cause of blood loss was not found. The anti-
Xa activity at the end of operation in this patient was 0.65 U/ml and the corresponding 
APTT value was more than 300 seconds. The preoperative APTT value in this patient 
was within the normal range. 
The APTT value intraoperatively before heparin administration was 47.3 seconds. Five 
minutes after heparinization the APTT value reached the maximum detectable value of 
300 seconds and remained on this level until the end of operation. 
DISCUSSION 
Bypass grafting has become the most widely applied and effective method of treating 
aonoiliac disease25 • In aonobifemoral bypass grafting systemic heparinization is 
common practice that attempts to prevent distal thrombotic complications during and 
after temporary occlusion of the aorta. The use of heparin in these procedures is mainly 
based on empirical grounds and its value has never been evaluated in a controlled 
prospective uial. 
Intraoperative heparin monitoring showed that the current methods for administering 
heparin may not provide an adequate degree of anticoagulation in all patients24"7• 
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Information gained from heparin monitoring provides insight into the actual level of 
anticoagulation and may be used to predict the amount of additional dosages of heparin 
if required. Whether this is effective in reducing the risks of complications due to large 
individual differences in heparin response and elimination rate needs to be determined. 
Another approach to overcome some of the heparin related complications may be the 
use of heparins with different pharmacological properties. In the current study we 
compared the pharmacokinetics of intravenously administered LMWH and UFH during 
aortobifemoral bypass prosthesis operations. At five minutes after heparin 
administration, no difference was observed in the anti-Xa activities induced by UFH 
and LMWH. The interindividual variation of anti-Xa activity in the LMWH group was 
smaller (SD:0.23) than in the UFH group (SD:0.43) and the anticoagulant effect, 
expressed as anti-factor Xa activity, was more sustained in the LMWH group: at 110 
minutes after administration, the levels were still in the therapeutical range of 0.2-0.5 
IU/ml as defined by others26.27. 
Surprisingly. the disappearance curves of the two heparins used in this study showed 
quite a similar shape as measured with the anti-Xa assay. This has not been reported 
before. 
We are aware of only one study that compared the effect of a LMWH and UFH during 
aortic graft surger/8 . In that study heparin was not administered intravenously before 
clamping, but injected into the aorta just distal to the clamp, which resulted in delayed 
appearance of peak levels of heparin activity. 
Which conditions existing in this study could have affected the pharmacokinetic 
behaviour of the heparin fragments? Firstly. shortly before completion of the 
anastomosis, the graft was flushed with variable amounts of a fluid containing 25 IU 
of UFH per ml normal saline solution. Since the two heparin assays employ different 
calibration curves, it is possible that the flushing of the graft is only detected in the 
UFH calibration curve (see arrow in figure I) and hence may influence the 
pharmacokinetic profile of UFH rather than that of LMWH. 
Secondly, the pharmacokinetics of the two heparins probably have a different metabolic 
basis. It has been suggested that elimination of heparin from the circulation is the result 
ll7 
of a combination of a saturable and a linear clearance curve". The saturable mechanism 
involves binding of heparin to endothelial cells and uptake into the reticulo-endothelial 
system"·". The non-saturable mechanism (""linear clearance") could be related to renal 
clearance32• High molecular weight forms of heparin are preferably eliminated by the 
saturable mechanism". while LMWH is predominantly cleared from the circulation by 
the non-saturable renal route34• This model is supponed by the observation in patients 
that severe chronical renal insufficiency did not alter the half-life of UFH, but strongly 
prolonged that of LMWH35• Also. the prolongation of the half-life of LMWH in 
nephrectomized rabbits was much more pronounced than that of UFH36 • Therefore it 
is conceivable that the large amounts of fluids infused during aonic surgery could have 
affected the renal clearance route of heparin. which would especially alter the 
pharmacokinetic behaviour of LMWH and not that of UFH. This is in agreement with 
the observation by others that the decay curves of UFH in patients undergoing vascular 
surgery are similar pre-and intraoperatively10• 
The finding that LMWH prolongs the APTT to a lesser extent than UFH and that the 
APTT values were not correlated with the anti-factor Xa levels in the LMWH group 
is in accordance with other stud1es2 1.37 ·3 ~. 
FbDP levels in plasma. i.e. cross-linked and non cross-linked derivatives of fibrin. 
increased significantly in both groups. This has also been reponed by others using a 
different assay specific for cross-linked fibrin degradation products"""'. The 
peroperative rise of FbDP levels could be explained by the surgical trauma which is 
known to trigger blood coagulation mechanism" but may also be caused by lysis of e.g. 
intravascular thrombi. The large standard deviation of the FbDP levels in the LMWH 
group (6.01 ug/ml) can be explained by the observation of very high FbDP values in 
one patient (13.2 ug/ml before heparin administration and 28.0 ug/ml after removal of 
the clamp). No clinical abnormalities were found in this patient. 
This study confirms earlier repons that administration of protamine on empirical basis 
is inadequate4•11 and that the anti-factor Xa activity of LMWH is. in contrast to that of 
UFH. not completely reversible by protamine (detectable levels ranged from 0.05 to 
0.42 IU/ml). This has clinical relevance because observations from clinical studies 
H8 
showed that plasma concentrations exceeding 0.4 anti-factor Xa !U/ml produce a 
critically enhanced risk ofbleeding44.ln our study no bleeding accident occurred in any 
of the patients receiving LMWH and the blood loss was comparable in both groups. 
In conclusion, following an intravenous bolus injection, the pharmacokineric profiles 
of LMWH and UFH show a similarity in patients undergoing aonobifemoral bypass 
grafting. 
REFERENCES 
I Murray G. Heparin in surgical treatment of blood vessels. Arch Surg 
1940.40:307-325 
2 Jacobsen W. Brauer F. Smith LL. Heparin activity monitoring during vascular 
surgery. Am J Surg 1978:136:141-144 
3 Quigley FG. Jamieson GO, Lloyd JV, Faris lB. Monitoring of heparin in 
vascular surgery. J Vase Surg 1988:8:125-127. 
4 Pone RJ. De Jong E, Knot EAR. De Maat MPM. Terpstra OT. Van Urk H, 
Greenland THN. Monitoring heparin and haemostasis during reconstruction of 
the abdominal aona. Eur J Vase Surg 1987;1:397-402 
5 Robinson MHE, Studley JON. Powis SJA. Anticoagulation in abdominal aortic 
aneurysm surgery: the approach of vascular surgeons in Great Britain and 
Ireland. Eur J Vase Surg 1989;3: 141-143 
6 Collins OJ. Kimbal DB. Rich NM. Andersen CA. McDonald PT. Heparin 
utilization during anerial vascularization. Am J Surg 1978:44:753-757 
7 Manny J, Romanoff H. Hyamm E. Manny M. Monitoring of intraoperative 
heparinization in vascular surgery. Surgery 1976;89:641-643 
8 Barner HB. The use of heparin in anerial reconstructions. Surg Gynecol Obstet 
1974;138:920 
9 House AK. Potter JM. Smith PA, Kennet D, Chester A. Heparinization in aortic 
surgery. J Cardiovasc Surg 1988:29:707-711. 
10 Williams NN, Brae PJ. Burke P. Meagher EA. o· Donoghue C, Otridge B, 
Bouchier-Hayes D. Heparin kinetics in vascular surgery. Eur J Vase Surg 
119 
1989;3:493-469. 
II Mabry CD, Thompson BW, Read RC. Activated clolling time (ACT) monitoring 
of intraoperative heparinization in peripherical vascular surgery. Am J Surg 
1979;138: 894-900 
12 Heimbecker RO. Systemic heparin in major vascular operations (editorial). Surg 
Gynecol Obstet. 1977;144:735. 
13 Effeney DJ, Goldstone J, Chin D. Krupski WC, Ellis RJ. Intraoperative 
anticoagulation in cardiovascular surgery. Surgery 1981;90(6):1068-1074 
14 De Swart CAM, Nijmeijer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously 
administered heparin in normal humans. Blood 1982;60:1251 
15 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities 
of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem 
J 1984;218:725 
16 Bratt G. Tomebohm E. Widlund L. Lockner D. Low molecular weight heparin 
(Kabi 2165. Fragmin): pharmacokinetics after intravenous and subcutaneous 
administration in human volunteers. Thromb Res 1986; 42: 613-620. 
17 Bakker M. Dekker PJ, Knot EAR, Van Bergen PFMM, Jonker JJC. Home 
treatment for deep venous thrombosis with low molecular weight heparin. 
Lancet 1988, nov 12:1142 (letter). 
18 Levine MN, Hirsch J. An overview of clinical trials with low molecular weight 
heparin fractions. Acta Chir Scand 1988;154 (suppl 543):73-79 
19 Harenberg J. Gnasso A. de Vries J, Zimmermann R. Augustin I. Anticoagulant 
and lipolytic effects of a low molecular weight heparin fraction. Thromb Res 
1985 ;39: 683 
20 Bratt G, Tomebohm E. Lockner D. Bergstrom K. A human pharmacological 
study comparing conventional heparin and low molecular weight heparin 
fragment. Thromb Haemost 1985;53:208 
21 Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and 
subcutaneous administration ofFragmin in deep venous thrombosis. Haemostasis 
1986;16 (suppl 2):25-29. 
120 
22 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a 
chromogenic substrate for activated factor X. Thromb Res 1976;8: 413-420 
23 Bascu D. Gallus A, Hirsch J, Cade J. A prospective study of the value of 
monitoring heparin treatment with the activated thromboplastin time. N Eng J 
Med 1972;287:324-327 
24 Kopperl PW. Hoegee-de Nobel E, Nieuwenhuizen W. A monoclonal antibody-
based enzyme immunoassay for fibrin degradation products in plasma. Thromb 
Haemostas 1988;59:310-315. 
25 Brewster DC, Darlit:g RC: Optimal methods of aortoiliac reconstruction. Surgery 
1978: 84: 739 - 748. 
26 Hirsch J, van Aken WG, Galius AS et al. Heparin kinetics and pulmonary 
embolism Circulation 1976:53:691-695 
27 Penner JA. Experience with a thrombotic clotting time assay for measuring 
heparin activity. Am J Clin Pathol 1974;61 :645-653. 
28 Melissari E, Stringer MD, Kakkar VV. The effect of a bolus injection of 
unfractionated or low molecular weight heparin during aortobifemoral bypass 
grafting. Eur J Vase Surg 1989;3:121-126 
29 Glimelius B, Busch C, Hoo M. Binding of heparin on the surface of cultured 
human endothelial cells. Thromb Res 1978:12:773 
30 Saba Hl, Saba SR. Morelli GA. Anti-heparin activity in human cells. Thromb 
Res 1986:42:355 
31 Mahadoo J, Hiebert J. Jacques LB. Vascular sequestration of heparin. Thromb 
Res 1977;12:79 
32 Piper J. The fate of heparin in rabbits after intravenous injection. Filtration and 
tubular secretion in the kidney. Acta pharmacologica 1947;3:373 
33 Palm M, Mattson Ch. Pharmacokinetics of heparin and low molecular weight 
heparin fragments (Fragmin) in rabbits with impaired renal and hepatic function. 
Thromb Haemostas 11987;58:932 
34 Boneu B. Caranobt. C. Gabaig AM, Dupouy D. Sie P. Buchanan MR, Hirsch 
J. Evidence for a saturable and reversible mechanism of clearance of standard 
121 
heparin in rabbits. Thromb Res 1987;46:845 
35 Goudable C, Ton That H, Damani A, Durand D, Caranobe C, Sie P, Boneu B. 
Low molecular weight heparin half life is prolonged in haemodialysed patients. 
Thromb Res 1986;43: I 
36 Caranobe C, Barret A, Gabaig AM, Dupouy D, Sie P, Boneu B. Disappearance 
of circulating anti-Xa activity after intravenous injection of standard heparin and 
low molecular heparin (CY 216) in normal and nephrectomized rabbits. Thromb 
Res 1985;40: 129 
37 Walenga JM, Fareed J, Petitou M, Samama M, Lormeau, JC, Choay J. 
Intravenous antithrombotic activity of a synthetic heparin penta saccharide in a 
human serum induced stasis thrombosis model. Thromb Res 1986; 43: 243 
38 Caner CJ. Kelton JG, Hirsch J, Cerkus A, Santos AV, Gent M. The relationship 
between the hemorrhagic and antithrombotic properties of low molecular weight 
heparin in rabbits. Blood 1982;59(6):1239-1245 
39 De Prost D, Ollivier V, Vie P, Benacerraf R, Duparc J, Khoury A. D-dimer and 
thrombin-antithrombin II complex levels uncorrelated with phlebographic 
findings in I 1 total knee replacement patients. Ann Bioi Clin 1990:48:235-238 
40 Jorgensen LN, Lind B. Hauch 0, Leffers A, Albrecht-Beste E, Konradsen LAG. 
Thrombin-antithrombin Il-complex and fibrin degradation products m 
plasma:surgery and post operative thrombosis. Thromb Res 1990;59:69-76 
41 Hauch 0, Jorgensen LN, Kolle TR. Wille-Jorgesen P, Nerstrom H, Neerstrand 
HS. Plasma cross-linked fibrin degradation products fraction D in patients 
undergoing elective abdominal surgery. Thromb Res 1988;51 :385-389 
42 Johnson EJ, Hariman H, Hampton KK, Grant PJ, Davies JA, Prentice CRM. 
Fibrinolysis during major abdominal surgery. Fibrinolysis 1990;4:147-151 
43 Grant PJ, Tate GM, Davies JA, Williams NS, Prentice CRM. Intraoperative 
activation of coagulation-a stimulus to thrombosis mediated by vasopressin? 
Thromb Heamost 1986:55:104-107 
44 Hirsch J, Ofosu FA. Levine M. The development of low molecular heparins for 
clinical use. In: Verstraete M. Yermylen J, Lijnen HR, Arnout J, eds. 
122 
Thrombosis and Haemostasis: Leuven University Press, 1987: 325-348. 
123 

Chapter 6 
DIAGNOSTIC VALUE OF QUANTITATIVE TESTS FOR FIBRIN 
DEGRADATION PRODUCTS IN DEEP VENOUS THROMBOSIS 
H. Kroneman'~. M. Berger', P.M.M. Bossuyt1, E.A.R. Knot2, 
J.H.P. Wilson', J.D.F. Habbema' 
Center for Clinical Decision Analysis', Erasmus University Rotterdam, Department of 
Internal Medicine If, University Hospital Rotterdam-Dijkzigt, Rotterdam, The 
Netherlands 
submitted for publication 
SUMMARY 
Laboratory diagnosis of deep venous thrombosis (DVT) has regained interest through 
development of enzyme immuno assays (EIA's) based on monoclonal antibodies for 
detection of fibrin degradation products (FbDP's) in plasma, This study was undertaken 
to evaluate the diagnostic value of these new assays in the diagnosis of DVT on the 
basis of reponed data in literature using receiver operating characteristics (ROC) 
methodology and Bayesiar1 analysis, Comparing test characteristics of the D-dimer 
assay for DVT at cutoff values as reponed in literature showed a significant difference 
between test performance in hospitalized and outpatients, By applying Bayes' rule on 
pooled data of hospitalized and outpatients separately, the relationship was calculated 
between D-dimer values, pre-test and post-test probabilities of DVT, It was concluded 
that test performance of the D-dimer assay for DVT is different in outpatients and 
hospitalized patients. Current diagnostic concepts concerning FbDP assessment in 
patients suspected for deep venous thrombosis should be adapted, 
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INTRODUCTION 
Laboratory assessment of fibrin and fibrinogen degradation products (FDP's) in deep 
venous thrombosis (DVT) has been practised for several years using different 
techniques (1-7). Most of these assays could only be performed on serum samples using 
polyclonal antibodies which cross-react with fibrinogen. Because serum is a source of 
artefacts (8), results obtained by these serum-based assays for FDP's should be 
interpreted with caution (9). As a consequence, the initial suggestion that determination 
of FDP's in serum could be of value in the diagnosis of DVT was abandoned. 
The issue of measuring FDP's in patients with DVT has regained interest through the 
development of quantitative enzyme immuno assays (EIA's) for their assessment (10-
15). These EIA ·s employ monoclonal antibodies against specific fibrin and fibrinogen 
epitopes which do not crossreact with fibrinogen. Furthermore, these assays permit 
discrimination between degradation products of fibrin (FbDP's) and fibrinogen 
(FgDP's) and can be performed on plasma samples, thereby avoiding the problems 
inherent in the use of serum. Clinical experience with the new assays is steadily 
growing and it is becoming clear that diagnostic concepts concerning FbDP assessment 
in patients suspected for DVT may have to be adapted. Therefore an evaluation of the 
diagnostic characteristics of these assays in patients suspected for DVT seems 
appropriate. 
Diagnostic tests are often characterized using the indices of sensitivity, which is the 
probability that the test result is positive in patients who have the disease (also called 
true positive rate) and spe~ificity, which is equivalent to the probability that the test is 
negative in patients who do not have the disease (also called true negative rate). Most 
of the published studies concerning DVT and the new assays for FbDP assessment have 
reported sensitivity and specificity based on single cutoff points to distinguish between 
diseased and non-diseased. The use of different cutoff points makes direct comparisons 
between studies difficult. Furthermore, the appropriate cutoff value in clinical practise 
depends on the patient population in which the test is used. 
By dichotomization of test results, the test is either positive or negative. valuable 
information may be lost, eg. suppose a hypothetical cutoff point of 20; in this case a 
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test result of 10.000 will be interpreted in exactly same way as a value of 21, although 
the probability of diseas~ may be considerably higher. A useful parameter to 
characterize clinical information without dichotomization is the likelihood ratio (LR), 
which is the ratio of the probability of a test result in diseased persons and the 
probability of the same test result in nondiseased persons (21). Another way, although 
also based on dichotomization, to obtain more information upon a diagnostic test is to 
determine sensitivity and specificity for different cutoff points. This is possible with 
EIA' s for FbDP' s since titey are quantitative tests yielding results distributed on a 
continuous scale, which may be reduced to an ordinal scale by categorizing the test 
variable. In this way, a variety of pairs is generated which can be plotted as a set of 
points in a unit square. This constitutes a receiver operating characteristic (ROC) curve. 
The area under a ROC cu·-ve is a measure of test performance and may be used for 
comparing tests (16-20). 
The post-test probability of disease can dramatically be affected by the prevalence or 
pre-test probability of disease: increase or decrease of disease prevalence will be 
accompanied respectively by a rise and fall of post-test probability. Hence, when 
interpreting test results oue should be aware of disease prevalence in the studied 
population. The relation between test result, pre-test and post-test probability of disease 
can be determined with Bayes' Theorem (21,22). 
The aim of this study was to evaluate the diagnostic value of the new assays for DVT 
by use of ROC methodology and Bayesian analysis on published data obtained in 
patients presenting with symptoms suggesting DVT. 
MATERIALS AND METHODS 
Materials 
The English language medical literature was searched for articles that have assessed 
diagnostic test characteristics ofElA's for fibrin degradation products in DVT. Because 
the first report that described an E!A for fibrin degradation products based on 
monoclonal antibodies was published in 1983 (II), we conducted a MEDUNE search 
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from january 1983 to january 1991 for articles discussing quantitative assessment of 
fibrin degradation products in plasma and deep venous thrombosis. In addition we 
reviewed the bibliographies of the articles found by the above method. Each article 
resulting from this search was screened and assessed for study design. Our criteria for 
inclusion of the articles in this study were: a blind comparison of the results of the 
index test with the current gold standard (ascending venography); a prospective 
evaluation of consecutive patients presenting with signs or symptoms suggesting DVT; 
a blind interpretation of test results and clear definition of criteria for test positivity of 
both index test and gold standard test. 
Methods 
ROC curves were constructed on the basis of data presented in each study fulfilling the 
inclusion criteria. True positive rates (or sensitivity) were plotted on the abcis~ false 
positive rates (or I minus specificity) on the ordinate. Cutoff points were chosen in 
such a way that the pairs of true-positive rates and false negative rates were evenly 
spaced along the ROC curves. The area under the ROC-curve was calculated by 
connecting the calculated points and adding the areas of the trapezoids underneath each 
pan of the curve. The standard errors associated with the areas were determined 
according to the Hanley-M:Neil algorithm (17). In comparing the area under two ROC 
curves, the two sample t-test was used. Within studies that determined test 
characteristics for hospitalized and outpatients separately. a comparison was made 
between the proportions of nonDVT inpatients and nonDVT outpatients with D-dimer 
levels exceeding the reported cutoff value. In testing differences between proportions, 
the Chi-square test for independent samples was used. All reported significance levels 
were two-sided and any probability less than 0.05 was considered to represent a 
significant difference. 
Post-test probabilities of DVT were calculated for different prevalences of DVT by use 
of the Odds form of Bayes' rule (21.22) which can be written as: 
P(DVT[T) 
P(noDVT[T) 
P(OVT) x P(T[ DVT) 
P(noDVT) P(T[noDVT) 
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where P(DVTIT) is the post-test probability of DVT given a test result T and P(DVT) 
is the prevalence of DVT in the population under investigation; P(TIDVT) is the 
probability of a test result given the presence of DVT; P(noDVTIT) is the probability 
of DVT absence given a test result and P(TinoDVT) is the probability of finding a test 
result given the absence of DVT. The quotient of P(TIDVT) and P(TinoDVT) is called 
the likelihood ratio (LR). 
RESULTS 
From a total of fifteen retrieved papers (13,14,23-35). four studies met our criteria for 
inclusion (32-35). Nine papers were not included in our study because test performance 
was evaluated in a population consisting of patients with confirmed DVT (!3,14,23-29), 
one because impedance plethysmography was used to confirm DVT (30) and one 
because only results of the semiquantitative latex agglutination assay were reponed 
(31). The results of the published reports that were included in our study are 
summarized in Table I. All studies used the 0-dimer assay for assessment of FbDP 
plasma levels. Results were calculated for hospitalized and outpatients separately in 
case this had not been done by the authors and could be extracted from the available 
data. Figure l shows the relative frequency distributions of the categoric D-dimer 
values in outpatients and hospitalized patients separately. As can be seen, most 
outpatients without OVT has lower D-dimer levels compared with nonOVT inpatients, 
whereas 0-dimer levels of inpatients with confirmed DVT were in general higher than 
those of outpatients. The areas of the ROC curves of individual studies obtained in 
outpatients were statistically not different (0.2 <p< 0.35). The same was true for the 
ROC areas of inpatients (p=0.23). Data of individual studies were pooled for 
hospitalized patients and outpatients separately. Comparison of the areas of the two 
pooled ROC curves showed that the ROC curve for inpatients (area: 0.80 ± 0.05) was 
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Table 1 Test characteristics of the D-dimer assay in patients suspected for DVT as reported in 
literature 
Size Population (ref) Capture Cutoff value Prevalence Sensitivity Specificity 
antibody (ng/ml) of DVT 
50 inpatients (32) DD-386/22 250 52% 100% 17% 
54 outpatients (32) DD-386/22 250 35% 100% 66% 
-108 outpatients (33) DD-386/22 200 36% 97% 65% "' 
-
108 outpatients (33) anti-FDP-D.D. 500 36% 97% 62% 
25 outpatients (34) anti-FDP-D.D. 200 20% 100% 50% 
25 outpatients (34) anti-FDP-D.D. 500 20% 86% 72% 
28 inpatients (34) anti-FDP-D.D. 200 50% 100% 7% 
28 inpatients (34) anti-FDP-D.D. 500 50% 100% 14% 
58 in+outpatients (35) DD-386/22 200 41% 100% 47% 
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Relative frequencies of categoric D-dimer values in outpatients and inpatients 
with symptoms suggesting DYT. 
not as good as for outpatients (area: 0.86 ± 0.03). although the difference was 
statistically not significant (p=0.14). The area of the ROC curve based on reported data 
obtained in a mixed population of hospitalized and outpatients (35) was not 
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significantly different as compared with that of pooled ROCs of inpatients (p=0.48) and 
outpatients (p=0.16). The pooled ROC curves are shown in Fig 2. 
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Roc curves of D-dimer in outpatients and inpatients for detection of DVT. 
Two studies determined test characteristics of the D-dimer assay for hospitalized and 
outpatients separately (32.34 ). One of these studies showed that the proportion of 
nonDVT patients with D-dimer levels above the reported cutoff value of 250 ng/ml was 
significantly higher (X2= 11.48. p<O.OO I) in the subgroup of inpatients when compared 
with outpatients (32). This finding was confirmed in the other study (34) using cutoff 
values of 200 ng!ml (X2=4.89, p<0.05) and 500 ng/ml (X2=6.64, p<O.OI). The 
relationship between D-dimer value. pre-test and post-test probabilities of DVT is 
shown in Table 2. Because of the relatively small sample size of inpatients, LR's in this 
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A. Outpatients 
Pre-test Post-test probability of DVT 
probability D-dimer levels 
ofDVT <200 200-500 500-1000 1000-2000 >2000 
10% 0.3% 14% 21% 31% 56% 
15% 0.4% 20% 30% 42% 67% 
20% 0.6% 27% 38% 50% 74% 
25% 0.8% 33% 45% 57% 79% 
30% 1% 38% 51% 63% 83% 
40% 2% 49% 62% 73% 89% 
50% 3% 59% 71% 80% 92% 
60% 4% 69% 79% 86% 95% 
70% 6% 77% 85% 90% 96% 
B. Inpatients 
Pre-test Post-test probability of DVT 
probability D-dimer levels 
ofDVT <200 200-500 500-1000 1000-2000 >2000 
10% 1% 2% 5% 11% 86% 
15% 2% 4% 7% 16% 9!% 
20% 3% 5% 10% 22% 93% 
25% 3% 7% 13% 27% 95% 
30% 4% 9% 16% 32% 96% 
40% 7% 13% 23% 43% 97% 
50% 10% 18% 3!% 53% 98% 
60% !4% 25% 40% 62% 99% 
70% 20% 34% 51% 72% 99% 
Table 2 Relationship between D-dimer levels (ng/ml), pre-test and post-test probability 
of DVT in o-utpatients (A) and inpatients (B) presenting with symptoms 
suggesting DVT. 
subgroup were obtained after applying logistic regression analysis on the square roots 
of the values. As can be seen from table 2, a rise of disease prevalence is accompanied 
by an increase of disease probability in each categoric D-dimer value. Funhermore, the 
presence of disease becomes more probable with higher D-dimer values for each of the 
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pre-test probabilities. 
DISCUSSION 
This study was undertaken to determine the role of measuring FbDP's plasma levels 
in the diagnosis of DVT. We used ROC methodology and Bayesian analysis on 
published data to assess diagnostic test performance of EIA's for FbDP's in patients 
clinically suspected of having DVT. ROC analysis is a convenient method for 
comparing diagnostic test performance and may provide insight into the practical use 
of diagnostic tests, because it shows various pairs of sensitivity and specificity which 
can be obtained by applying different cutoff values. Although test characteristics are 
claimed to be independent of pre-test probability, reponed sensitivities and specificities 
differ greatly between inpatients and outpatients (Table I). After transforming data into 
ROC curves, it was demonstrated that the areas of individual studies obtained in 
outpatients and inpatients were comparable, which suggests that test results are 
comparable within these subgroups. 
As mentioned. the area of the pooled inpatients ROC curve was smaller as compared 
with that of outpatients. although this difference was not significant. Comparing 
sensitivities and specificities in hospitalized and outpatients at reported single cutoff 
points showed, however, that test performance of the D-dimer assay was not 
comparable between these subgroups. This is illustrated in Table 2: In case the 
prevalence of DVT is 20%, the finding of a D-dimer value between 200 and 500 ng/ml 
predicts the presence of DVT in outpatients with a probability of 27%, whereas the 
probability for DVT in hospitalized patients is only 5%. The D-dimer distributions of 
both DVT and nonDVT inpatients are shifted to the right when compared to outpatients 
(Fig. I). A possible explanation for this difference may be a higher incidence of co-
morbodity interfering with the coagulation system in hospitalized patients suspected for 
DVT. 
In the diagnostic process the clinician, after having been supplied with a numerical 
value of the D-dimer test result, is interested in the probability of DVT. This post-test 
probability, however. depends on two conditions: I. given a certain test value, the post-
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test probability of disease will change in the same direction with the prevalence. 2. 
given a certain pre-test probability. the probability of disease varies with the test value. 
The relation between test result, pre- and post-test probability can be calculated with 
Bayes' rule and is illustrated in Table 2. Suppose an outpatient with a pre-test 
probability for DVT of 20% (prevalence in outpatients); in this case the finding of a 
low D-dimer value, eg <200 ng/ml, implies that the probability of DVT reduces to 
0.6% (i.e. the probability for DVT absence is± 99%), whereas a D-dimer value of 
1500 ng/ml indicates the absence of DVT with a probability of 50%. Even so, in case 
of a fixed D-dimer result of 400 ng/ml, the probabilities for absence of DVT may range 
from 23% to 86%. depending on the pre-test probability (10%-70%) in the studied 
outpatient population (Table 2). After the test result is known. the physician must 
choose between doing nothing (ruling out the diagnosis). obtain additional diagnostic 
information or treat. The decision to withhold therapy depends on the no-treatment 
threshold. which is a measure of the balance between the benefits of treatment to 
diseased patients (B) and the risks of treatment to healthy patients (R). The optimal 
cutoff point of a diagnostic test can be determined by applying Bayes' rule and the 
specification of a risk/benefit ratio. The latter is difficult to estimate because life 
expectancy and quality of life should also be taken into account in assessment of a 
treatment risk/benefit ratio. However. it is obvious that the treatment threshold 
probability for DVT is low. i.e. it has high benefit to patients with DVT (prevention 
of fatal pulmonary embolism) and relatively low risk (bleeding) to nonDVT patients. 
The relationship between post-test probability for DVT and the risk/benefit ratio is 
described in the following formula: 
P(DVTIT) = R 
P(noDVTIT) B 
Suppose the benefit of treatment is 5 times higher than the risk, then the threshold post-
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test probability for DVT is ± 17%. The corresponding cutoff value can now be derived 
from Table 2 for each pre-test probability of DVT, e.g. in hospitalized patients with a 
pre-test probability of 40%, the appropriate cutoff value would be 500 ng!ml; the 
treatment threshold is not reached in case the pre-test probability for DVT is 70%. The 
relationship between post-test probability and D-dimer values for the above mentioned 
pre-test probabilities of DVT in hospitalized patients is shown in Figure 3. 
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Relationship between post-test probability and D-dimer levels (ng/ml) at fixed 
pre-test probabilities of DVT in hospitalized patients. 
This is just an example of how a cutoff point could be assessed and does not 
necessarily imply that this should be the optimal cutoff point for clinical use. The 
appropriate cutoff point depends on the patient population in which the test is used: eg. 
the pre-test probability of DVT in hospitalized patients after total hip replacement is 
considerably higher as compared with that of outpatients, hence the cutoff point 
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necessary to obtain an equal post-test probability for absence of DVT must be higher 
in the hospitalized group. 
In conclusion, evaluating D-dimer test results with ROC methodology on reported data 
demonstrated that D-dimer test characteristics were comparable for individual studies 
in outpatients and hospitalized patients separately. The D-dimer assay performs 
significantly different in outpatients when compared with hospitalized patients in the 
diagnosis of DVT at reported cutoff points. 
By applying Bayes theorem on pooled data of in- and outpatients, posterior 
probabilities for DVT could 3be calculated in relation to categorized D-dimer values 
and different prior probabilities. Based on this analysis, the optimal cutoff point can be 
calculated by combining Bayes rule and estimating a treatment risk/benefit ratio. A 
reconsideration of the clir.ical utility of FbDP assessment in the diagnosis of DVT 
seems warranted on the basis of available evidence on test characteristics. 
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DISCUSSION 
During the last decades insight into the mechanism underlying the formation of fibrin 
and its degradation has increased markedly. This progress has provided a basis for the 
development of techniques for assessment of the two opposing processes of coagulation 
and fibrinolysis. 
There are many components in blood which influence the overall fibrinolytic activity 
which can be measured in a clinical setting. However, three markers of fibrinolysis 
have emerged as being of paramount importance. These are tissue plasminogen 
activator (t-PA), plasminogen activator inhibitor (PAl) and fibrin/fibrinogen degradation 
products (FDP). While speculation may still exist about the role of measuring activators 
and inhibitors of plasminogen, there is agreement that fibrinolysis is reflected by 
generation of fibrin and fibrinogen degradation products. Therefore, the most tangible 
evidence for ongoing fibrinolysis in blood is the formation of fibrin an fibrinogen 
degradation products. 
The main difference between the formerly used serum based assays for FDP assessment 
and the newly developed &ssays is, that the latter assays can be carried out in plasma 
using monoclonal antibodies, which makes it possible to avoid serum artifacts. 
Furthermore, these new plasma assays permit discrimination between degradation 
products of fibrin and of fibrinogen (chapter 1 ). 
We found that fibrinogen degradation products (FgDP) are generally well correlated 
with degradation products of fibrin (chapter 2). One may speculate about the origin of 
the plasma FgDP fraction: it is unknown whether this FgDP fraction originates from 
circulating fibrinogen or the fibrin-fibrinogen complex in the circulation. It is possible 
that plasmin. which lysis fibrin. also digests a part of the fibrinogen molecule before 
its action is terminated by a,-antiplasmin. The observation of good correlations between 
the FgDP fractions and degradation products of fibrin suggests that primary fibrinogen 
digestion in the circulation is a frequent event. which is associated with secondary 
fibrinolysis. 
We examined the role of the D-dimer assay for the diagnosis of deep venous 
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thrombosis (DVT). Analysis of published studies showed that test performance of the 
D-dimer assay for DVT at reported cutoff values was different in hospitalized patients 
when compared with outpatients (chapter 6). This can be explained by the higher 
incidence of co-morbidity interfering with the coagulation system in the first group. It 
was demonstrated that very low levels of D-dimer could predict the absence of DVT, 
whereas very high levels of D-dimer confirmed the presence of DYT. This finding 
suggests that the D-dimer assay may be used for the diagnosis of DVT. but is in 
contrast to the results of our study with the D-dimer assay in outpatients, which was 
performed at the Thrombosis Service Centre of Rotterdam (chapter 3). The test 
characteristics of the D-dimer assay in this study (sensitivity 92%, specificity 21%, 
negative predictive value 88% ,positive predictive value of 28%) were disappointing. 
This discrepancy may be explained that the fact that lPG was used to confirm DVT 
instead of ascending venography, which is less sensitive detecting calf vein thrombosis. 
The effectiveness and feasibility of the D-dimer assay for the diagnosis of deep venous 
thrombosis can be demonstrated by a management study. Other clinical applications of 
the assays for fibrin and fibrinogen degradation products may concern the monitoring 
of treatment (chapter 5) and the course of disease (chapter 4 ). In general, detection of 
fibrin(ogen) derivatives by monoclonal antibody based assays provides valuable 
information on haemostasis in diseases associated with an activated state of coagulation. 
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SUMMARY 
This thesis comprises clinical and methodological studies employing newly developed 
plasma assays for assessment of fibrin and fibrinogen degradation products (FDP's) on 
patients with diseases or conditions characterized by an activated state of coagulation. 
In the introduction the mechanism of the haemostatic balance is briefly summarized 
based on current insights and it is described that disturbance of this balance may have 
two different clinical outcomes: bleeding or thromboembolism. The importance to 
obtain information regarding the state of the haemostatic balance in patients at risk for 
developing thromboembolism and/or bleeding is emphasized. The aims of the studies 
are defined. 
In chapter I the disadvantages of existing serum FOP assays. based on polyclonal 
antibodies. are described. The newly developed FOP assays employ monoclonal 
antibodies which do not cross-react with fibrinogen and can be performed on plasma 
samples, thereby avoiding the disadvantages inherent in the use of serum samples. A 
summary is given of the currently available FOP assays in plasma and their clinical 
relevance has been reviewed as reported in literature. The aims of the studies were 
defined on the basis of this review. 
In chapter 2 we have evalu~ted four different plasma FOP assays in healthy volunteers, 
patients with cirrhosis of the liver and patients suspected for deep venous thrombosis 
(OVT). Plasma FOP levels. as assessed by different assays, showed a good correlation 
in each (sub)group of patients. In general, the correlations between plasma FOP assays 
were lower in normals than in patients. It was first seen that secondary fibrinolysis 
appeared to be associated with fibrinogenolysis in cirrhosis of the liver and OVT. 
In chapter 3 the diagnostic value of the D-dimer assay for deep venous thrombosis 
(OVT) is studied in 232 outpatients clinically suspected of having OVT. The Sensitivity 
and specificity of the 0-dimer assay for OVT were 92% and 21% respectively. The 
OVT prevalence was 25% and the predictive value of a negative and positive test result 
were 88% and 28% respectively. It was concluded that the D-dimer assays has limited 
value, either to confirm or to exclude OVT. 
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In chapter 4 the fibrinolytic response in patients with gram-negative septic shock is 
studied. In the past, disturbance of haemostasis in septic shock was considered to 
depend largely upon extreme activation of the coagulation pathway. It has recently been 
suggested that fibrinolysis may be impaired during septic shock. Measurement of 
plasma FgDP and TDP plasma levels in patients with septic shock showed that the 
fibrinolytic activity was comparable in survivors and nonsurvivors. The process of 
ongoing fibrinolysis during septic shock is evidenced by elevated TDP and FgDP 
plasma levels. It was concluded from this study that the fibrinolytic system remains 
activated during septic shock. 
In chapter 5 we focused on heparinization during vascular surgery. During aortic graft 
surgery. heparin is administered on empirical basis and is associated with a wide 
variation in patient response and elimination rate which makes it difficult maintain 
predictable or adequate levels of anticoagulation for all patients. The recently developed 
low molecular weight heparins and the FDP plasma assays may be used to place 
heparin administration during vascular surgery on a rational scientific basis. We studied 
the pharmacokinetics of low molecular weight heparin (LMWH) and unfractionated 
heparin (UFH) during aortobifemoral bypass grafting. It was demonstrated that plasma 
FbDP levels showed a significant rise intraoperatively in both patients groups, which 
could be explained by lysis of intravascular thrombi. FbDP levels correlated moderately 
with anti-factor Xa in the LMWH group, but not in the UFH group. Whether this may 
be used to define dose regimen for heparin administration needs to be determined by 
furtber studies. lt was concluded that the pharmacokinetic profiles of UFH and LMWH 
showed a similarity after intravenous bolus injection in patients undergoing 
aortobifemoral bypass grafting and that the anti-Xa activity in the LMWH group was 
more sustained as compared with the UFH group. 
In chapter 6 the value of plasma FDP assays for the diagnosis of disease is evaluated 
in a broader sense. This chapter comprises an analysis of published studies on the 
diagnostic value of the plasma FDP assays for deep venous thrombosis (DVT). Test 
performance of the D-dimer assay for DVT at reported cutoff values was different in 
hospitalized patients when compared with outpatients. The relationship between D-
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dimer levels, pre-test and post-test probabilities of DVT were calculated. Very low 
levels of D-dimer could predict the absence of DVT, very high levels of D-dimer 
confirmed the presence of DVT. It was concluded that the D-dimer assay may be used 
in the diagnosis of DVT and current diagnostic concepts concerning FDP assessment 
in patients suspected for DVT should be adapted. 
In the discussion has been outlined that assessment of fibrin and fibrinogen degradation 
products is the most tangible evidence for ongoing fibrinolysis, and secondary 
fibrinolysis appears to be associated with fibrinogenolysis. Whether assays for fibrin 
degradation products can be used in daily clinical practise for diagnosis of deep venous 
thrombosis can be determined by management studies. Application of the assays on 
patients with diseases associated with an activated state of coagulation allows detailed 
information on the haemostatic balance. 
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SAMENVATTING 
In dit proefschrift worden klinische en methodologische studies beschreven naar fibrine 
en fibrinogeen afbraakprodukten in ziekten of condities met een gestoorde haemostase. 
De studies zijn uitgevoerd met recent ontwikkelde, op monoclonale antilichamen 
gebaseerde enzyme immuno assays. 
De inleiding gaat in op bet mechanisme van het haemostase evenwicht. Een verstoring 
van deze balans kan twee verschillende klinische gevolgen hebben: bloedingen of 
trombo'embolieen. Om therapeutische redenen is bet van belang te weten waar het 
evenwicht ligt bij patienten met een verhoogd risico op bloedingen of trombo-
embolieen. De doelstellingen van de studie worden uiteengezet. 
Hoofdstuk 1 geeft een literatuuroverzicht van de beschikbare laboratoriumtesten voor 
fibrine en fibrinogeen afbraakprodukten (FDP). De nadelen van reeds Ianger bestaande 
serum FDP assays worden besproken. De recent ontwikkelde FDP testen zijn gebaseerd 
op monoclonale antilichamen. die niet kruisreageren met fibrinogeen. en kunnen worden 
uitgevoerd met plasma samples. Hierdoor worden de nadelen, welke inherent zijn aan 
het gebruik van serum samples. venneden. 
In hoofdstuk 2 worden vier verschillende plasma FDP assays geevalueerd in patienten 
met levercirrhose, patienten die worden verdacht van diep veneuze trombose (DVT) op 
basis van het klinisch beeld, en in niet zieke vrijwilligers. De plasma FDP 
concentraties, bepaald door verschillende assays. correleren goed met elkaar in de 
verschillende patienten groepen. doch minder goed in de groep van niet zieke 
vrijwilligers. Op theoretische gronden mag worden verwacht, dat de berekende som van 
de FbDP (fibrine afbraal,produkten) en FgDP (fibrinogeen afbraakprodukten) 
concentraties gelijk is aan de bepaalde TDP (totaal aan fibrin and fibrinogeen 
afbraal.:produkten) concentratie. Wij hebben echter geen verklaring kunnen vinden voor 
de discrepantie tussen de TDP waarden en de berekende som van de FbDP en FgDP 
concentraties in 4 patienten met DVT en 1 patient met klinische symptomen van DYT, 
waarbij de diagnose niet kon worden gesteld. In deze studie wordt voor het eerst 
aangetoond, dat secondaire fibrinolyse gepaard gaat met fibrinogenolyse in levercirrhose 
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en DVT. 
In hoofdstuk 3 wordt de diagnostische waarde van de D-dimer assay voor DVT 
bestudeerd. De studie werd ge"initieerd omdat er behoefte bestaat aan een simpele niet-
invasieve laboratoriumtest voor bet vaststellen van DVT. 232 poliklinische patienten 
met verdenking op een trombose been zijn onderzocht. De sensitiviteit en specificiteit 
van de D-dimer assay zijn respectievelijk 92% en 21%, de voorspellende waarde van 
een positief en negatief test resultaat bedragen respectievelijk 88% en 28% bij een DVT 
prevalentie van 25%. Uit het onderzoek wordt geconcludeerd, dat de D-dimer een 
geringe diagnostische waarde heeft voor DVT. 
In hoofdstuk 4 wordt de fibrinolytische respons beschreven in patiemen met een gram-
negatieve sepsis. In het verleden werd de verstoring van de haemostase bij septische 
shock voornamelijk toegeschreven aan sterke activatie van de stollingscascade. Recent 
onderzoek suggereen. dat de fibrinolyse geremd kan zijn tijdens septische shock. Deze 
studie werd uitgevoerd om de mate van fibrinolytische activiteit te bepalen door het 
meten van de eindprodukten van de fibrinolyse. Plasma FgDP en TDP concentraties 
zijn verhoogd. maar niet significant verschillend in suiVivors en nonsurvivors van een 
septische shock. De studie toont aan, dat de fibrinolyse geactiveerd blijft tijdens gram-
negatieve septische shock en dat de mate fibrinolytische activiteit in survivors en 
nonsurvivors van een septische shock vergelijkbaar is. 
ln hoofdstuk 5 wordt ingegaan op het probleem van heparine toediening bij 
aortobifemorale bypass chirurgie. Tijdens deze ingrepen wordt op empirische basis 
ongefractioneerd heparine (UFH) toegediend. Dit gaat gepaard met een grote variatie 
in patient respons en eliminatiesnelheid, waardoor het moeilijk is voorspelbare en 
adequate anticoagulantie te verkrijgen in aile patienten. In de studie wordt de 
farmacokinetiek van UFH en laag moleculair heparine (LMWH) vergeleken tijdens 
aonobifemorale bypass operaties. lntra-operatief vindt een significante stijging plaats 
van de FbDP concentratie> in plasma. hetgeen verklaard kan worden door lysis van 
intravasculaire trombi. FbDP concentraties correleren matig met de anti-Xa activiteit 
in de LMWH groep, maar niet met de anti-Xa activiteit in de UFH groep. Nader 
onderzoek is nodig om te bepalen. of de FbDP assay een bijdmge kan leveren bij het 
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vaststellen van een adequate LMWH dosis. Het farmacokinetisch profiel van LMWH 
en UFH blijkt vergelijkbaar na een intraveneuze bolus injectie. De anti-Xa activiteit in 
de LMWH groep houdt !anger aan dan die in de UFH groep. 
In hoofdstuk 6 word! de waarde van de plasma FDP assays voor de diagnose van DVT 
geanalyseerd op basis van gepubliceerde studies. De testeigenschappen van de D-dimer 
assay voor DVT bij vermelde cutoff points zijn verschillend bij klinische patienten in 
vergelijking met poliklinische patienten. Dit kan worden verklaard door een hogere 
incidentie van co-morbiditeit, die interfereert met het stollingssysteem in klinische 
patienten. Zeer !age D-dimer waarden zijn vrijwel bewijzend voor de afwezigheid van 
DVT, terwijl zeer hoge D-dimer waarden de diagnose DVT bevestigen. Plasma FDP 
assays kunnen een belangrijke rol gaan spelen in de laboratoriumdiagnose van DVT. 
In de discussie wordt onderstreept, dat de nieuwe testen voor fibrine en fibrinogeen 
afbraakprodukten waardevolle informatie opleveren over de heamostase in verschillende 
ziektebeelden. Als directe klinische toe passing wordtde diagnostiek van DVT genoemd. 
Andere mogelijke roepassingen betreffen het monitoren van het beloop van ziekten die 
gepaard gaan met een gestoorde haemostase en het monitoren van therapie. 
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